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ABSTRACT OF THE DISSERTATION
Molecular Mechanisms That Govern Human Cardiac Stem Cell Age Disparity
by
Tania Fuentes
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, June 2015
Dr. Mary Kearns-Jonker, Chairperson

Transplantation of adult endogenous cardiovascular progenitor cells for heart
repair results in some clinical benefit, however these stem cells lack the regenerative
capacity unique to neonatal cardiovascular stem cells. The goal of this work was to
identify mechanisms that contribute to the decline of cardiac stem cell regenerative
ability with age and investigate novel therapeutic strategies to improve cardiac stem cell
function. When comparing neonatal and adult cardiovascular stem cell clones, both cell
types were capable of cardiomyogenic differentiation. However, the expression levels of
forty-one microRNAs were significantly altered with age. Expression differences were
correlated with reduced proliferation and a limited capacity to invade in response to
growth factor stimulation in adult progenitors. This information can be utilized to
develop novel therapeutics and improve outcomes after stem cell-based treatment for
heart failure.

xiii

CHAPTER ONE
INTRODUCTION

The ability of stem cells to stimulate repair of the heart, an organ once thought to
be static and unable to regenerate, has the potential to transform modern medicine. Each
year, an estimated 620,000 Americans have a new coronary attack and 295,000 have a
recurrent attack (Go et al., 2014). On average it takes over an hour for a patient to
receive medical attention (Fosbøl et al., 2013; Rasmussen et al., 2014), and once a patient
is treated, there is significant heart muscle damage. Various types of stem cells capable
of cardiac differentiation have been advanced to human clinical trials in an effort to repair
the injured heart (R. Bolli et al., 2011; Delewi et al., 2014; Karantalis et al., 2014).

Bone Marrow Mononuclear Cells
More than 50 clinical trials using bone marrow mononuclear cells (BMMCs) as a
cell-based therapy for the infarcted heart have been completed (Delewi et al., 2014).
Unfractionated BMMCs are a heterogeneous mixture of cell types containing monocytes,
lymphocytes, haematopoietic progenitor and precursor cells and an occasional
haematopoietic stem cell. Thus far, the transplantation of unfractionated bone marrow
mononuclear cells for heart injury has an excellent safety profile (Xu, Ding, Zhao, Pu, &
He, 2014). The functional outcomes after transplantation, however, tend to be wideranging. Some have attributed heterogeneity in functional outcomes to differences in
protocols for BMMC harvest, isolation, storage, and delivery (Wollert, 2015). Others
have attributed the inconsistency of functional outcome to data integrity (Nowbar et al.,

1

2014). An analysis of 49 clinical trials, including both fully randomized and not fully
randomized trials, revealed that there is a positive correlation in number of discrepancies
in published work and the reported percentage improvement in LVEF (Nowbar et al.,
2014). Meta-analyses that only include fully randomized clinical trials have determined
that the benefit in left ventricular ejection fraction after BMMC transplantation either for
myocardial infarction or chronic heart failure falls somewhere between 2.55 – 3.54%
(Delewi et al., 2014; Xu et al., 2014). This modest benefit, although promising is not
sufficient to completely ameliorate loss of function after heart injury.

Induced Pluripotent Stem Cells
Induced pluripotent stem cells (iPSCs) have not yet advanced to clinical trials but
are a cell type that is capable of cardiomyogenic differentiation and holds promise for
regenerating the heart. Induced pluripotent stem cells originate as differentiated cells
that, through the introduction of defined factors, gain a state of pluripotency functionally
similar to embryonic stem cells. iPSC can be generated through viral-mediated
overexpression of proteins (Giorgetti et al., 2009; Haase et al., 2009; Martinez-Fernandez
et al., 2009; Takahashi & Yamanaka, 2006) or small RNAs (Anokye-Danso et al., 2011;
S.-L. Lin et al., 2008; Miyoshi et al., 2011). However, due to cancer concerns, non-viral
methods such as exposure to protein extracts (Park et al., 2014) or defined chemicals
(Hou et al., 2013) have also been developed to reprogram cells.

iPSC-derived Cardiac Progenitors
Induced pluripotent stem cells can be utilized to form cardiovascular progenitors
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by partially differentiating iPSCs into cardiomyocytes, these cardiovascular progenitors
can be stably maintained in culture once differentiation-inducing signals are eliminated
(Cao et al., 2013). iPSC-derived multipotent cardiovascular progenitors have the ability
to form all three cardiovascular lineages (Carpenter et al., 2011; B. Lin et al., 2012; Lu et
al., 2013; Alessandra Moretti et al., 2010; Nsair et al., 2012), and once differentiated,
cardiomyocytes derived from iPSC multipotent cardiac progenitors can form electrically
and mechanically coupled large-scale 2D cell cultures with mature electrophysiological
properties (Christoforou et al., 2013). Human iPSC-derived multipotent cardiovascular
progenitors, when seeded into a decellularized heart, migrate, proliferate, and
differentiate into cardiovascular lineages. After 20 days, seeded hearts exhibited
spontaneous contractions and generated mechanical force (Lu et al., 2013). In vivo, when
transplanted into the rat myocardium, human iPSC-derived multipotent cardiac
progenitors were retained long term (10 weeks) with evidence of differentiation into cells
of cardiac lineage (Carpenter et al., 2011).
Not all partially differentiated pluripotent cells, have an equal propensity for
cardiac lineage differentiation. In mice, sorting for the cell surface marker combination
of VEGFR1 and VEGFR3 can enrich for an iPSC-derived Isl1+/Nkx2.5+ cardiac
progenitors with trilineage cardiovascular potential in vitro. Twenty-eight days posttransplantation in vivo, there was evidence of cardiovascular progenitor cell engraftment
and differentiation into mature cardiomyocytes in vivo (Nsair et al., 2012). Similarly,
expression of VEGFR2 (KDR) in mouse iPSC-derived cardiac progenitors can separate
multipotent progenitor functional ability. Transplantation of KDR+ cells results in
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superior functional benefits and a greater number of vascular structures when compared
with KDR– cells (Mauritz et al., 2011).

Human iPSC in Large Animal Models
To date, the majority of studies completed in large animal models with iPSCs
have utilized transplantation of human iPSCs once the cells have been successfully
differentiated into relevant cardiovascular lineages.
Transplantation of cardiomyocyte cell sheets derived from human iPSC after
ischemic cardiomyopathy significantly improved cardiac performance and attenuated left
ventricular remodeling with no teratoma formation in pigs (Kawamura et al., 2012).
After 8 weeks, however, few cells survived within the myocardium. Improved cell
survival can be achieved with transplantation of highly vascularized omentum flap tissue
along with iPSC-derived cardiomyocyte sheets (Kawamura et al., 2013). Transplantation
of human iPSC-derived endothelial cells and smooth muscle cells into swine following
ischemia-reperfusion injury can improve c-kit+ cell recruitment, vascular density, and
ATP turnover rate after 4 weeks. This treatment also improves blood flow and
contractile function in the border zone (Xiong et al., 2013). Combination of iPSCderived cardiomyocytes, endothelial cells, and smooth muscle cells, when administered
in pigs with a fibrin patch containing IGF-1 significantly improves left ventricular
function, decreases infarct size, and reduces apoptosis after myocardial infarction (L. Ye
et al., 2014).

Considerations for iPSC Clinical Use
In spite of promising results after application of iPSC (both differentiated and
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undifferentiated) as a cell-based therapy for cardiac injury in large animals, there are
several roadblocks that must be overcome before iPSC transplantation can feasibly be
considered for use in a clinical setting. The whole process of reprogramming tends to be
mutagenic resulting in chromosomal alterations and a significant number of copy number
variants (Gore et al., 2011; Hussein et al., 2011; Ji et al., 2012; Park et al., 2014).
Furthermore, induced pluripotent stem cells, although genetically reprogrammed, retain
an epigenetic memory (including unique DNA methylation patterns) of their cell type of
origin (Ohi et al., 2011). This epigenetic memory can result in an inherent predisposition
towards differentiation into a given cell type (Rizzi et al., 2012). Therefore, induced
pluripotent stem cells derived from easily accessible tissues such as the skin, may not be
as ideal for cardiac transplantation as other cell types which are closer to the cardiac
lineage. Optimization of reprogramming and differentiation methods is necessary to
ensure that the iPSCs and iPSCs-derived cells fully mimic the desired cell type
Although induced pluripotent stem cells are an innovative and readily accessible
source of cardiovascular progenitors, the possibility of cancerous transformation and low
efficiency of reprogramming with non-viral methods present a significant barrier to their
use in clinical practice.

Human Endogenous Cardiac Stem Cells
Of the cell types investigated for their ability to regenerate the heart after injury,
resident cardiac progenitor cells (CPCs) are a preferred cell type because of their high
propensity for cardiomyogenic differentiation, relative safety, and lack of cancerous
transformation when transplanted in vivo (Konstantinos Malliaras et al., 2014b). When
compared with stem cells that reside outside of the heart such as bone marrow-derived

5

mesenchymal stem cells, adipose-tissue-derived mesenchymal stem cells, or bone
marrow mononuclear cells, resident cardiac progenitors have a higher capacity for
cardiomyogenic differentiation and paracrine signaling resulting in greater improvements
in cardiac function after transplantation in vivo (Koninckx et al., 2011; Li et al., 2012;
Takehara et al., 2008). In human clinical trials, utilization of resident cardiac stem cells
as a cell-based treatment after myocardial infarction have shown that these cells can
reduce infarct size and result in improvements in patient outcomes lasting at least 1-2
years (R. Bolli et al., 2011; Makkar et al., 2012; Konstantinos Malliaras et al., 2014b).
Several stem cell types have been isolated from the heart and defined on the basis
of surface phenotype including ckit+ cells, cardiospheres, cardiosphere-derived cells, and
ISL1+ cells (Table 1). Which of these cells types is most optimal for cardiovascular
regeneration is unknown. In this chapter we will summarize the current literature on
heart-derived cardiac stem cells.

Ckit+ Cardiac Stem Cells
Ckit+ cardiac stem cells (CSCs) are isolated from the heart by enzymatic
digestion and sorted on the basis of tyrosine protein kinase, ckit, expression and absence
of leukocyte common antigen, CD45. Ckit antigen expression can be found in a variety
of tissues within the body (Lammie et al., 1994). Ckit+ cells isolated from the heart have
the ability to form all three cardiac lineages (Claudia Bearzi et al., 2007). According to
Bearzi et al. (2007), these cells typically do not express CD34, CD31 (platelet/endothelial
cell adhesion molecule), or KDR (kinase insert domain receptor) and a small percentage
(0.5%) of ckit+ cardiac stem cells express GATA4 (gata binding protein 4) and Nkx2.5
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Table 1.

Markers that define human heart-derived stem cells*

Ckit+ Cardiac Stem Cells
(Bearzi et al., 2007)

Negative for: CD45, CD34, CD31, KDR
Positive for: Ckit

└ Vascular Ckit+ Stem Cells
(Bearzi et al., 2009)

Negative for: CD45, CD34, CD133, αSA
Positive for: Ckit, KDR, CD31low, TGF-β1low

└ Myogenic Ckit+ Stem Cells
(Bearzi et al., 2009)

Negative for: CD45, CD34, CD133, CD31, TGFβ1, KDR
Positive for: Ckit, αSAlow

└ Endothelial Ckit+ Stem Cells
(Sandstedt et al., 2010)

Negative for: CD45
Positive For: Ckit, KDR, CD31, CD34, CXCR4

└ Ckit+ cardiac stem cells
(Koninckx et al., 2011)

Negative for: CD140, CD34, CD133, CD45, FGF
Positive for: CD13, CD29, CD44, CD73, CD90,
EGFR (lost Ckit expression with passaging)

└ Lin Depleted Ckit+ CSCs
(He et al., 2011)

Negative for: CD45, CD34, CD133, CD31, KDR
Positive for: Ckit

└ non-Lin depleted Ckit+ CSCs
(He et al., 2011)

Negative for: CD45, CD34, CD133
Positive for: Ckit, KDR, CD31

Cardiospheres
(Davis et al., 2009)

Negative for: CD45, CD34
Positive for: Core (Ckit, Nkx2.5, connexin 43,
Desmin) Periphery (CD31, CD105, αMHC, cTnI,
CD133, MDR-1, CD90)

Cardiosphere-derived Cells
(Li et al., 2012)

Negative for: CD45, CD34, CD31, CD133
Positive for: Ckitlow, CD105, CD29, CD90low

ISL1+ Cardiac Progenitors
(Serradilfalco et al., 2011)

Positive for: ISL1, Ckit (only identified in fetus)

└ Ckit+ ISL1+ CPCs
(T. Fuentes et al., 2013)

Negative for: HLADr
Positive for: ISL1, Ckit, CD73, CD105, CD44,
CD13, IGF1R, CXCR4, CXCR7, HLA class I,
CD140a

└ hESC-derived ISL1+ CSCs
(A. Moretti et al., 2006)

Negative for: Tbx5
Positive for: ISL1, KDR, Nkx2.5, Gata-4, Tbx20,
Tbx1
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└ hESC-derived ISL1+ CSCs
(Bu et al., 2009)

Negative for: KDR, Nkx2.5
Positive for: ISL1

└ hESC-derived ISL1+ CSCs
(K. O. Lui et al., 2013)

Negative for: Neurofilament
Positive for: ISL1, VEGFR1, KDRlow

*Modified from (Tania Fuentes & Kearns-Jonker, 2013)
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(cardiac-specific homeo box) (Claudia Bearzi et al., 2007). Sandstedt et al. (2014) using
single cell PCR analysis found that 81% of these cell express vWF, 72% express KDR,
and 1.1% express Nkx2.5 and suggested that instead of being truly multipotent, this
population consists of some already lineage committed progenitors, more specifically
endothelial progenitors (Sandstedt et al., 2014; Sandstedt, Jonsson, Lindahl, Jeppsson, &
Asp, 2010).
The role of ckit+ cardiovascular progenitors in myocardial regeneration is highly
debated (Molkentin, 2014; Nadal-Ginard, Ellison, & Torella, 2014a, 2014b; Torella,
Ellison, & Nadal-Ginard, 2014; van Berlo et al., 2014). Ellison et al found that ablation
of endogenous cardiac stem cells abolishes regeneration after myocardial damage.
Recovery of myocardial regeneration can be achieved by exogenous administration of the
progeny of one ckit+ cardiac stem cell (Ellison et al., 2013). After regeneration, selective
suicide of transplanted cells and their progeny abolishes regeneration, severely impairing
ventricular performance (Ellison et al., 2013). This suggests that the ckit+ cardiac stem
cell is mainly responsible for the regenerative capacity of the heart.
Critics of this idea include van Berlo et al (2014) who, using a genetic lineage
tracing, reported that endogenous c-kit+ cells produce new cardiomyocytes within the
heart but at a very low percentage of approximately 0.03 or less which may be
functionally insignificant to myocardial regeneration. Consistent with this, Senyo et al
found, using pulse-chase and genetic fate mapping, that the genesis of cardiomyocytes
with age occurs mainly through the division of pre-existing cardiomyocytes, and that this
process increases after myocardial injury (Senyo et al., 2013). Whether or not ckit+ cells
contribute significantly to the cardiomyocytes within the heart after injury, although
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highly debated, may not be as important as their paracrine role in regeneration. A recent
study by Hong et al found that despite rapid disappearance of ckit+ cardiac stem cells
following transplantation, intracoronary delivery of stem cells significantly improved left
ventricular function at 35 days post-transplant. Therefore, functional improvement may
be not be dependent on survival and differentiation of transplanted cells (Hong et al.,
2014).
Because of the inherent heterogeneity of stem cells sorted on the basis of ckit and
absence of CD45 expression, subpopulations of ckit+ cardiovascular progenitors have
differing functional properties. Ckit+ cardiovascular progenitors that also express KDR
tend to be found in epicardial coronary arteries, arterioles, and capillaries and are
vascular progenitors whereas KDR- Ckit+ cardiovascular stem cells are found in the
myocardial interstitium and are myogenic progenitors (C. Bearzi et al., 2009). Insulinlike growth factor-1 receptor expression can also separate functionally distinct ckit+
progenitors. Transplanted IGF1R+ ckit+ cardiac stem cells can significantly increase
infarcted tissue regeneration (12mm) when compared with IGF1R- cardiac stem cells
(7mm). Pretreatment of these cells with IGF-2 can further improve tissue regeneration
(15mm) and ejection fraction (D'Amario et al., 2011). Cardiac stem cells (because they
use asymmetric chromatid segregation when dividing) can also be subdivided by the
integrity of their DNA. Kajstura et al found that transplantation of cells that retained the
template DNA when compared with ckit+ cardiac stem cells with the synthesized copy of
DNA resulted in a greater restoration of infarct thickness (60mm3 vs 25mm3) and a
greater attenuation of diastolic wall stress (Kajstura et al., 2012).
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The percentage and functional properties of ckit+ cardiac stem cells within the
heart is not consistent from person to person (Gambini et al., 2012; Song et al., 2013).
Females have a greater number of ckit+ cardiac progenitors in their heart than males
(Itzhaki-Alfia et al., 2009) and failing hearts can have as many as 4 times the number of
ckit+ cardiac progenitors (Kubo et al., 2008). Aging can also play a role in stem cell
distribution and function. The total number of ckit+ cardiac stem cells in the heart
decreases dramatically after the first month of life (Mishra et al., 2011). Even well into
adulthood, age remains a factor in the yield of ckit+ cardiac stem cells that can be
obtained from a tissue biopsy (Aghila Rani, Jayakumar, Sarma, & Kartha, 2009). With
age, the percentage of senescent ckit+ stem cells in the heart increases, as demonstrated
by telomere shortening, attenuated telomerase activity, telomere dysfunction- induced
foci, and the expression of cyclin-dependent kinase inhibitor 1A and 2A (Cesselli et al.,
2011). In young stem cells, pretreatment with Ephrin A1 prior to transplantation resulted
in enhanced speed of CSC migration, a 37% decrease in infarct size (2 fold greater than
CSC alone), and a significant increase in ejection fraction and left ventricular developed
pressure (Goichberg et al., 2011). In aged stem cells, on the other hand, elevated levels
of reactive oxygen species interfered with receptor auto-phosphorylation and downstream
signaling resulting in inhibition of migratory ability in vitro and impaired translocation in
vivo in the damaged heart. Overexpression of functionally intact Ephrin type-A receptor 2
in old CPCs corrected the defects in signaling and enhanced cell motility (Goichberg et
al., 2013).
In spite of evidence to the contrary, the old heart is not devoid of functional
cardiac stem cells, both senescent CSCs with extremely short telomeres and
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phenotypically young CSCs carrying long, intact telomeres co-exist within the aged
heart. The CSCs with long telomeres, however, are quiescent and do not re-enter the cell
cycle or form differentiated progeny (Sanada et al., 2014). Therefore strategies to isolate
or activate these phenotypically young stem cells within the aged heart are necessary to
enhance regeneration.

Ckit+ Cardiac Stem Cells in Large Animals
Few studies have utilized ckit+ cardiac stem cells in large animal models. Bolli et
al delivered ckit+ cardiac stem cells into the infarct-related artery three months after
ischemia-reperfusion injury in pigs (n=11). This resulted in significantly greater ejection
fraction (51.7±2.0% versus 42.9±2.3%, P<0.01 by echo) when compared with controls
(n=10) at one month post infusion. Green fluorescent protein-labeling of CSCs allowed
for identification of CSC differentiation into cells that expressed cardiac troponin I,
troponin T, myosin heavy chain, and connexin 43. There was also evidence of labeledCSCs forming vascular structures that expressed alpha-smooth muscle actin (R. Bolli et
al., 2013).
Welt et al injected 1.6 million ckit+ CSCs 6 weeks after coronary ligation in the
canine heart, and measured long-term changes in outcomes after 30 weeks. In the celltreated group (n=13), the ejection fraction remained stable from 6 weeks to 24 weeks
post-infarct (30.5% to 32.9%) when compared with the control group (n=6) which
declined during the same time frame (35.2% to 26.4%). This suggest that the favorable
outcomes after cell therapy can potentially last long-term (Welt et al., 2013).
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A combination treatment of CSCs along with mesenchymal stem cells (MSCs)
results in additive improvements in heart regeneration. Human cardiac stem cells at a
dose of 1 million cells and MSCs at a dose of 200 million cells were administered 14
days after myocardial infarction in Yorkshire swine. After 4 weeks, there was a 2-fold
greater reduction in infarct size (21.1% combo, n=5 vs 10.4% ckit+ CSCs alone, n=5 and
9.9% MSCs alone, n=5) and a 7-fold enhanced engraftment in the combination cell
therapy group when compared to either cell therapy alone. In all cell treated groups,
ejection fraction was restored to baseline whereas in control (n=5) it remained
persistently depressed (Williams et al., 2013).

Cardiospheres and Cardiosphere-derived Cells
Cardiospheres are exclusively heart-derived stem cells (White et al., 2013) that
are treated with specific growth medium to form non-adherent sphere-like structures
(Smith et al., 2007). The core of cells within the cardiosphere contains cells that express
ckit, nkx2.5, and desmin (Davis et al., 2009). Cardiospheres also have a percentage of
cells that are CD45+, these cells do not play a role in cardiosphere formation and their
function in regeneration is unclear (J. Ye et al., 2013). Cardiospheres when plated and
grown as a monolayer are called cardiosphere-derived cells (CDCs). When compared
with other cell types such as bone marrow-derived mesenchymal stem cells, adipose
tissue-derived mesenchymal stem cells, and bone marrow-derived mononuclear cells,
CDCs have superior angiogenic potential and secrete higher levels of angiogenic and
antiapoptotic factors. In vivo transplantation of CDCs, when compared with these other
cell types, results in the highest improvements of cardiac function and highest levels of
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cell engraftment after myocardial infarction (Li et al., 2012). The mechanism for the
regeneration of viable myocardium after CDCs transplantation is mediated mainly
through upregulation of host cardiomyocyte cycling and recruitment of endogenous
progenitors (K. Malliaras et al., 2013).
Cardiosphere-derived cells retain their ability to form sphere-like structures
(secondary cardiosphers) when exposed to epidermal growth factor (Chimenti et al.,
2010). Exposure of CDCs to epidermal growth factor can also significantly improve
functional parameters such as migration, proliferation, and wound healing of CDCs
(Aghila Rani & Kartha, 2010). Secondary sphere formation can enhance the
functionality of cardiosphere-derived cells. The 3-D formation of the cardiospheres when
compared with the monolayer of cardiosphere derived cells has higher levels of Troponin
I (Machida, Takagaki, Matsuoka, & Kawaguchi, 2011). When transplanted into the
infarcted myocardium, secondary cardiospheres result in higher levels of engraftment,
greater improvements in left ventricular dysfunction and reduced infarct size when
compared with transplantation of CDCs alone (Cho et al., 2012).
Cardiospheres have the unique advantage of diverse cell types within a natural 3D formation which mimics the stem cell niche. This periphery of supporting cell
populations have a paracrine role that enhances regeneration (Davis et al., 2009). In spite
of the superior regenerative effects after cardiosphere transplantation when compared
with CDCs, their relatively large size is a disadvantage and presents safety concerns.
Cardiospheres exert a dose-dependent functional benefit, with higher doses resulting in
greater benefits (Shen, Cheng, & Marban, 2012), however transplantation of large
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numbers of cardiospheres via intracoronary infusion may result in adverse events such as
microembolism therefore cardiosphere-derived cells are more widely used.
The majority of the benefit after CDC transplantation is mediated through
secreted factors and cell-to-cell signaling. Direct differentiation of CDCs after
transplantation only accounts for 20-50% of increases in myocardial viability and
capillary density (Chimenti et al., 2010). This was measured by injecting human cells
into SCID mice and measuring the origin of regenerated tissues. Only 9.6% of the total
capillaries were found to be of human origin which amounts to approximately 20% of
enhanced angiogenesis, and only 11.8% of myosin heavy chain expressing cells in the
myocardium were of human origin accounting for half of the 20% increase in relative
tissue viability (Chimenti et al., 2010).
Transplantation of both syngeneic and allogeneic CDCs significantly improves
infarct size, infarcted wall thickness, and ejection fraction after transplantation, compared
to controls even though the number of retained cells significantly drops at 3 weeks (K.
Malliaras et al., 2012). This suggests that paracrine secretions rather than direct
differentiation are mainly responsible for functional improvement as cells do not engraft
long-term. When transplanted in vivo, CDCs secrete VEGF, HGF, and IGF1, and in vitro
CDC-conditioned media exerts an antiapoptotic effect on neonatal rat ventricular
myocytes, a proangiogenic effect on human umbilical vein endothelial cells, and can
reverse angiotensin II-mediated contractile dysfunction in adult cardiomyocytes
(Chimenti et al., 2010; Maxeiner et al., 2010). The paracrine activity of CDCs is
regulated by the ERK pathway. In ERK stimulating conditions growth factors such as
VEGF have increased secretion, whereas in ERK inhibitory conditions cells are more
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prone to cardiomyogenic differentiation (H. J. Lee, Cho, Kwon, Park, & Kim, 2013).
CDCs also secrete exosomes which play a large role in their regenerative ability.
Exosomes isolated from CDC conditioned medium inhibits cardiomyocyte apoptosis,
promotes cardiomyocyte proliferation, and enhances angiogenesis of endothelial cells.
Injection of exosomes into the heart of injured mice can recapitulate the benefit of CDC
transplantation (Ibrahim, Cheng, & Marban, 2014).
Paracrine secretions can also influence the plasticity of surrounding cell types.
Mesenchymal stem cells derived from the mediastinal fat when exposed to cardiosphere
conditioned medium partially differentiate towards the cardiac lineage (Siciliano et al.,
2015). Although the benefit of CDC transplantation is mainly paracrine mediated, in
vivo, transplantation of CDC conditioned media alone does not result in equal
improvements in left ventricular ejection fraction and number of cycling cardiomyocytes
when compared with transplantation of CDCs. In vitro, direct cell to cell contact results
in the greatest enhancement of cardiomyocyte proliferation compared with CDCs grown
in a transwell contact-free system (Xie et al., 2014).
Although the heterogeneity of cell types within cardiosphere-derived cells
contribute to their therapeutic efficacy, some cell types are not required for their benefits.
A cell type commonly within the CDC population is the CD90 population. CD90
expression usually identifies a mesenchymal/myofibroblast cell. This cell type when
isolated from cardiospheres displayed a reduced cardiac differentiation potential when
compared with CD90- cells (Gago-Lopez et al., 2014). In vivo, depletion of cells that
express CD90 prior to transplantation in a mouse model of myocardial infarction
augments the functional potency of CDCs resulting in a ~7% increase in LVEF above
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transplantation of CDCs alone (Cheng, Ibrahim, et al., 2014). Most interestingly,
depletion of another common cell type within CDCs, the ckit+ cardiac stem cell, does not
compromise the structural and functional benefits of CDCs in a mouse model of
myocardial infarction. In the CADUCEUS clinical trial, there was no correlation between
percentage of ckit+ cells and the benefit of CDC transplantation in humans (Cheng,
Ibrahim, et al., 2014). Therefore, the cell type responsible for the therapeutic benefits
after CDC transplantation are distinct from ckit+ cardiac stem cells.
With disease, the characteristics of cardiosphere-derived cells changes. Some of
these alterations can negatively influence CDC function, CDCs cultured from diabetic
patients had 1.6-fold more CD90+ cells than those from non-diabetic patients (Chan et
al., 2012). Other disease-induced modifications can surprisingly improve CDC function.
CDCs from end-stage heart failure patients demonstrated a significantly higher
restoration of ventricular function, prevented adverse remodeling, and enhanced
angiogenesis after transplantation in an infarcted rodent model when compared to control
heart disease patients (Cheng, Malliaras, et al., 2014; Sharma et al., 2015). These
positive changes were found to be due to an enhanced secretome activity of end stage
heart failure-derived CDCs.
Cardiospheres and Cardiosphere-derived Cells in Large Animals
There have been several studies that have utilized large animal models to study
the therapeutic efficacy of cardiosphere-derived cell transplantation. Some have used
human cells in large animals. In a cyclosporine A immunosuppressed pig, Takehara et al
(2008) transplanted human CDCs or bone marrow-derived mesenchymal stem cells with
basic fibroblast growth factor in a slow release hydrogel after myocardial infarction.
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Four weeks after transplantation, mesenchymal stem cells with bFGF (n=6) did not
significantly increase LVEF above bFGF alone (n=8). Whereas, transplantation of CDCs
with bFGF (n=9) resulted in an additive effect over bFGF alone and significantly
increased LVEF (38.4% vs 30.1% baseline) and regional wall motion (58.5% vs 46.2%
baseline) which was significantly evident when compared with the change in cardiac
function in the control group (n=6). In pigs that received CDCs, thirty-three percent of
cardiomyocytes generated from the transplanted cells were the result of direct
differentiation rather than cell fusion as confirmed by immunohistochemical
colocalization of the human Y chromosome with sarcomeric alpha actin. In pigs that
received mesenchymal stem cells only 10% of cardiomyocytes were the result of direct
differentiation (Takehara et al., 2008).
Others have employed pig cardiosphere-derived cells delivered either
syngeneically or allogeneically. Cardiosphere derived cells have a diameter of 21μm
which when compared with the 7-10µm capillary luminal diameter is relatively large.
Therefore infusion of high numbers can result in microvascular occlusion and infarct
(Johnston et al., 2009). Regeneration of tissue without microvascular infarction can be
achieved with transplantation of ≥107 CDCs (300,000/kg) but less than 2.5 x 107 CDCs.
Unfortunately, due to low levels of engraftment, transplantation of 107 CDCs by overthe-wire balloon catheter (n=7) did not significantly improve left ventricular mass, infarct
size, end-diastolic volume, end-systolic volume, left ventricular ejection fraction or enddiastolic pressure. However, cardiac magnetic resonance revealed that CDC treatment
did decrease relative infarct size (19.2% to 14.2% of left ventricle infarcted, P=0.01),
whereas placebo did not (17.7% to 15.3%, P=0.22) after 8 weeks (Johnston et al., 2009).
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To improve engraftment an open-chest surgery with twenty intramyocardial
injections of either cardiospheres or cardiosphere-derived cells was used in pigs four
weeks post myocardial infarction (S. T. Lee et al., 2011). After 24 hours engraftment
regardless of dose (0.5 million, 2 million, or 10 million) was 8-9% in remote normal
myocardium. In the peri-infarct zone, however, engraftment was inversely related to the
number of injected cells with the lowest dose of cell (0.5million) resulting in the highest
percentages of engraftment. By ventriculography, both cell-treated groups (cardiospheres
n=8, CDCs n=10) had a significant increase in LVEF when compared with the placebo
group (n=11, p<0.01). In 2 animals lacZ labeling was used to trace cell fate, after 8
weeks, the expression of lacZ was confirmed in cardiomyocytes, however whether these
are due to direct differentiation or cell fusion is unknown. Cardiosphere and
cardiosphere-derived cells had very similar outcomes with cardiosphere transplantation
resulting in superior improvements in end-systolic elastance, delta end-diastolic pressure,
and apical septal thickening (S. T. Lee et al., 2011).
Allogeneic transplantation of mismatched CDCs by intracoronary infusion in a
porcine model 2-3 weeks after myocardial infarction revealed that in large animals
allogeneic transplantation (n=5) can attenuate remodeling, improve global and regional
function, decreased scar size, and increase viable myocardium when compared with
vehicle (n=5) 2 months post-treatment (Konstantinos Malliaras et al., 2013). Left
ventricular ejection fraction was preserved in cell-treated (∆ -0.5, p=0.73) when
compared with control animals (∆ -9.9, p<0.001). By MRI, scar size was unchanged in
controls (∆ 0.4%, p=0.33) but decreased in CDC-treated animals (∆ -3.6%, p=0.026).
There was also a significant increase in viable myocardial mass in CDC-treated animals
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(∆ 10.7 g) when compared with controls (∆ 2.7 g, p=0.003) after 2 months. Although
allogeneic transplantation results in mild local mononuclear infiltration, there is no
systemic immunogenicity associated with mismatched CDC transplantation. Cardiac
retention after 24 hours was only 4.3% using luciferase labeled CDCs. At 2 weeks post
infusion cells could still be detected within the recipient myocardium, however by 2
months, no allogeneic cells were detected (Konstantinos Malliaras et al., 2013).
CDCs also have beneficial effects when administered very early after myocardial
infarction. When applied this early, they can be used as therapy to prevent
cardiomyocyte death as opposed to a therapy to regenerate lost tissue. Kanazawa et al
(2015) conducted a short-term (48 hours) study of CDC administration 30 minutes after
reperfusion to investigate relative safety as an adjunctive therapy to reperfusion in
porcine model of myocardial infarction. Comparison of doses revealed that higher doses
of allogeneic CDCs (7.5 or 10 million cells, n=5 each) rather than low dose (5 million
cells, n=5) resulted in cardioprotection. Transplantation of ~8.7 million cells (n=4)
resulted in significant decreases in TUNEL positive cardiomyocytes within the border
zone after 48 hours. There was also a significantly smaller infarct size in the CDC-treated
group (59.7%) when compared with sham (81.0%, n=5) or placebo (80.3%, n=5) as well
as a decrease in microvascular obstruction area when compared with controls (Kanazawa
et al., 2015).

Current Clinical Trials
On the basis of the promising outcomes in large animal work, administration of
endogenous cardiac stem cells as a therapy for cardiac injury has moved into human
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clinical trials. Currently there are four phase I, safety and efficacy, clinical trials
completed.
The clinical trial entitled, “Intracoronary cardiosphere-derived cells for heart
regeneration after myocardial infarction” or CADUCEUS trial was led by Eduardo
Marban. This trial included 25 patients (17 cell-treated, 8 standard care) who received a
dose of autologous CDCs. Cell therapy, after 6 months, resulted in reductions in scar
mass (p=0.001), increases in viable heart mass (p=0.01) and regional contractility
(p=0.02), and regional systolic wall thickening (p=0.015) by MRI. At this time point,
changes in end-diastolic volume, end-systolic volume, and LVEF did not differ between
groups (Makkar et al., 2012). At 12 months, transplantation of CDCs resulted in a
significant reduction in scar mass (11.9g decrease) and significant increase in viable mass
(22.6g increase). There was also improved regional contractility and regional systolic
wall thickening. However, at 12 months, functional measurements of end-diastolic
volume, end-systolic volume, and LVEF did not differ significantly between groups
(Konstantinos Malliaras et al., 2014a). At 12 months the only serious adverse event
determined by the data safety monitoring board to be possibly related to CDC therapy
was a non-ST-segment elevation MI in 1 CDC-treated patient at 7 months after cell
infusion.
One of the largest clinical trials completed to date, using endogenous
cardiovascular stem cells, is the “Administration of cardiac stem cells in patients with
ischemic cardiomyopathy” or SCIPIO trial. This trial led by Roberto Bolli, had a total of
33 patients (20 cell-treated, 13 control) and tested the safety and efficacy of ckit+ cardiac
stem cells (Roberto Bolli et al., 2012; Roberto Bolli et al., 2011). Ckit+ stem cells were
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isolated from the right atrial appendage, grown to sufficient numbers (maximum 106
CSCs) and injected during coronary artery bypass grafting surgery 4 months after
myocardial infarction. After 2 years, there were significant improvements in left
ventricular ejection fraction (41.7% at 2 years vs 29.7% at baseline). This was
accompanied by an increase in left ventricular viable mass (12.2% increase) and decrease
in infarct size (15.7% decrease). Other outcome measures such as the New York Heart
Association classification and the Minnesota Living With Heart Failure Questionnaire
score also improved significantly after 2 years. No CSC-related adverse effects were
reported.
The clinical trial entitled, “Transcoronary Infusion of Cardiac Progenitor Cells in
Patients With Single Ventricle Physiology” or TICAP is one of the only clinical trials in
young patients with hypoplastic left heart syndrome and is led by Hidemasa Oh (Ishigami
et al., 2014). Fourteen patents (average age 1.8+/- 1.5 years) were enrolled in this study
and received autologous CDCs ~30 days after staged procedures. No serious adverse
events were reported in the 18-month follow-up. CDC-treated patients had increased
cardiac function as measured by left ventricular ejection fraction at 3 months (52.1% vs
46.9% at baseline) this increase persisted over the period of follow up (54.0% at 18
months). In contrast control patients had no significant increase in heart function at 3
months (47.7% vs 46.7% at baseline) which was not significantly changed during the
follow-up period (48.7% at 18 months).
Cardiac stem cell transplantation, as evidenced by these three completed clinical
trials, can result in improved patient outcomes, however full regeneration of the injured
myocardium is likely to be achieved with a combination of cell types (Latham et al.,
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2013) and growth factors delivered in an engraftment-promoting medium (Mayfield et
al., 2014). Experiments in large animals and human clinical trials have highlighted the
utility of administration of select growth factors (without cardiac stem cells) to ameliorate
cardiac injury (Braitsch, Kanisicak, van Berlo, Molkentin, & Yutzey, 2013; Gao et al.,
2010; Henry et al., 2003; Hibbert et al., 2014; Jabbour et al., 2011; Koudstaal et al., 2014;
Silverberg et al., 2001; Simons et al., 2002; Tritos & Danias, 2008). A summary of
results from human clinical trials with growth factors administered after cardiac injury
can be found in table 2.
The last of the completed clinical trials, which was completed by Hiroaki
Matsubara in Japan, is the only clinical trial that uses both cardiac stem cells and bFGFinfused biodegradable hydrogel. This clinical trial is entitled, “Autologous Human
Cardiac-Derived Stem Cell to Treat Ischemic Cardiomyopathy” or ALCADIA (Nakata et
al., 2012) and uses stem cells from endomyocardial biopsisies, which express CD105,
CD90, CD29, Nanog, Oct4, Gata4 and are negative for CD45. These CSCs (5 x 105
cells/kg) were delivered using 20 intramyocardial injections which were covered with a
biodegradable gelatin hydrogel which contained 200µg of infused bFGF. Six patients
with ischemic cardiomyopathy were enrolled in this study. This study has not yet
published final results. Preliminary data after 6 months indicate an improvement in
LVEF in the cell-treated patients (from 26.7% to 35.8% by 3D Echo and 22.6% to 34.7%
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*Modified from (Kathy O Lui, Zangi, & Chien, 2014)

Summary of paracrine factors used in clinical trials for myocardial repair.*
Phase
Patient type and no.
Results
Randomized,
Chronic heart failure,
An increase of 5.5% and a decrease of 5.4%
controlled trials n=32
in LVEF in the treatment and control groups,
respectively
rhFGF2
Phases I and II Coronary artery
No improvement in exercise tolerance or
disease, n=337
myocardial perfusion at day 180. Significant
reduction in angina was observed at day 90
but not at day 180 compared to that of the
placebo group.
rhG-CSF
Randomized,
Acute MI, n=560 in 14 No statistically significantly difference in LVEF
controlled trials trials (285 ctrl, 275
vs placebo, no significant adverse effects
treated)
rhGrowth
A mixture of
Congestive heart
LVEF +4.3% (above baseline, most benefit in
hormone
controlled and failure, n=212 in 14
uncontrolled trials). Increased left ventricular
uncontrolled
studies
mass and wall thickness.
trials
rhNeuregulin-1
Phase I
Chronic heart failure,
LVEF +4.1% (above baseline), p<0.001 at
n=15
12 weeks. Adverse side effects were
reported.
Phase II
Chronic heart failure,
No statistically significant difference in LVEF
n=44 (11 ctrl, 33
vs placebo, adverse effects with high
treated)
(1.2µg/kg) dose.
rhVEGF
Phase I (VIVA Coronary artery
High dose (50ng/kg) improved angina by day
trial)
disease, n=178 (63 ctrl, 120 compared to placebo.
115 treated)
Phase I
Coronary artery
Improved myocardial perfusion at rest in a
disease, n=14
dose-dependant manner.
Abbreviations - rh: recombinant human protein; LVEF: left ventricular ejection fraction

Table 2
Factor
rhEPO

(Braitsch et al., 2013)

(Henry et al., 2003)

(Gao et al., 2010)

(Jabbour et al., 2011)

(Tritos & Danias, 2008)

(Hibbert et al., 2014)

(Simons et al., 2002)

Ref
(Silverberg et al., 2001)

by MRI), as well as a decrease in infarct volume/left ventricular mass (%) by MRI (from
23% to 19.7%). There was also a concomitant decrease in wall motion score (from 17.2
to 6.6). Maximum aerobic exercise capacity (VO2 peak) was increased by 4.5ml/kg/min.
Of the 6 patients, one patient experienced an acute occlusion of a graft and was excluded
from further evaluation and one experienced worsening heart failure during follow-up.
No other adverse events were reported. Comparison with matched controls has not been
reported.
There are two clinical trials using endogenous cardiac stem cells that are currently
enrolling participants. The first is a phase I/II clinical trial led by Eduardo Marban and is
the first trial to investigate the allogeneic use of endogenous cardiac stem cells in
humans. This trial is entitled, “Allogeneic Heart Stem Cells to Achieve Myocardial
Regeneration” or ALLSTAR. The primary endpoint is to test the safety of allogeneic
cardiosphere-derived cell product. This study expects an enrollment of 274 patients.
Cells will be transplanted <3 months or 3-12 months after myocardial infarction to assess
the ideal time frame for cell delivery. At present, there are no released outcomes from
this trial.
The second is a phase II trial entitled PERSEUS and is a follow up trial on the
phase I TICAP trial. This trial uses cardiac progenitor cell infusion to treat univentricular
heart disease. This study has an estimated enrollment of 34 patients with hypoplastic left
heart syndrome between the ages of 0 and 20 years of age. The primary endpoint is to
measure cardiac functional improvement after 3 months. Cardiac function will also be
measured after 12 months. This study is currently enrolling patients and is expected to be
completed in 2018.
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Considerations for Transplantation of Endogenous CSCs
There is growing evidence for the benefit of using allogeneic cardiac progenitors
for cardiac transplantation (K. Malliaras et al., 2012; Tseliou et al., 2013). However, it is
unclear whether an immune response to these cells would negate their benefits when
transplanted in humans. The transplantation of allogeneic stem cells is likely to lead to
T-cell mediated rejection by either indirect allorecognition, or through polymorphic
variants of donor MHC being recognized by recipient T cells (Nehlin, Isa, & Barington,
2011). This T-cell mediated rejection is mediated by the expression of both MHC class I
and co-stimulatory molecules including CD40, CD80, and CD86 (Nehlin et al., 2011).
Without the presence of the co-stimulatory molecules, MHC class I binding to T cell
receptors results in anergy, apoptosis of T cells, or tolerance-inducing immunoregulation
(Nehlin et al., 2011).
Results of experiments using ckit+ cells in vitro suggest they actually help reduce
inflammation by activating T-regulatory cells through the expression of programmed
death ligand 1. They also lack the expression of CD40, CD80 or CD86 which are costimulatory molecules needed for conventional allogeneic T-helper 1 or T-helper 2 type
responses (Lauden et al., 2013). However, further studies using allogeneic ckit+ stem
cells in vivo are needed. Studies with other types of endogenous cardiac progenitors have
similar results. Cardiosphere-derived cells express class I MHC antigens but not class II
antigens or B7 co-stimulatory molecules (K. Malliaras et al., 2012). The absence of
MHC class II gives cells the potential to escape recognition by alloreactive CD4+
lymphocytes (Tasso & Pennesi, 2009). In culture, they elicit negligible lymphocyte
proliferation and inflammatory cytokine secretion and when transplanted in vivo into an
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infarcted rat heart, they cause a mild local immune reaction, without histologicallyevident rejection or systemic immunogenicity with similar sustained benefits to
syngeneic transplantation at 6 months post injection (K. Malliaras et al., 2012).
Cardiospheres in vitro inhibited proliferation of alloreactive T cells, and interestingly
when transplanted in vivo attenuated the inflammatory response observed histologically
in the peri-infarct area (Tseliou et al., 2013).
Although stem cells seem to have a low immunogenic profile, once transplanted
they do not survive long-term (Konstantinos Malliaras et al., 2013). This may due to the
fact that differentiated progeny of transplanted allogeneic pluripotent stem cells are
rejected by the host immune system (Nussbaum et al., 2007). During differentiation,
hESC express very low levels of surface MHC1 molecules but following implantation
they differentiate and up-regulate MHC expression thus triggering effective immune
responses (Calderon et al., 2012). Some would argue that although allogeneic CPCs are
eventually rejected, much of the benefit of cell transplantation is due to indirect
mechanisms such as paracrine secretion or activation and recruitment of existing
endogenous stem cells. Therefore, allogeneic transplantation may still be beneficial if
rejection is delayed long enough to allow cells to exert their protective and regenerative
paracrine effects (K. Malliaras et al., 2012).
Overall, endogenous cardiac progenitors are a promising cell-based therapeutic
for the heart. They have relative safety as there have been no adverse events such as
cancer or arrhythmias. Thus far, they have demonstrated a relatively low immunologic
profile and can result in functional benefits that last 1-2 years. Yet cells are rarely
retained long-term. Malliaras et al demonstrated that 24 hours after intracoronary infusion
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the percentage of cells that engrafted within the heart was 4.3% (Konstantinos Malliaras
et al., 2013). It is likely that enhanced engraftment could result in improvements in
existing outcomes. The greatest benefits will most likely come from transplantation of
carefully selected cell types that have been pre-treated for optimal functioning, within an
engraftment promoting medium.

ISL1+ Cardiac Progenitors
One of the endogenous cardiovascular progenitor types that has yet to be used in
clinical trials is the ISL1+ cardiac progenitor. Islet-1 (ISL1) is a protein that is expressed
by stem cells early during cardiovascular development and is essential for cardiogenesis;
progenitors that express ISL1 are required for the formation of the right ventricle, atria
and outflow tract (Cai et al., 2003). Addition of purified ISL1 protein to human
embryonic stem cells during differentiation, can increase the number of cardiac cells
produced 3-fold (Fonoudi et al., 2013). This highlights the utility of ISL1 expression in
cardiogenesis. In vitro, ISL1+ progenitor cells are capable of forming all three
cardiovascular lineages (Bu et al., 2009). Despite their clear role in cardiovascular
development, the ability to isolate ISL1+ cardiac progenitors from the human heart
decreases with age. In the young heart there are abundant levels of ISL1+ progenitor
populations, yet with increasing age, ISL1+ cardiac progenitors are reduced to reportedly
nonexistent levels (Simpson et al., 2012). Comparison of neonatal ISL1+ cardiac
progenitors with similarly isolated adult progenitors that are negative for ISL1 revealed
that, after transplantation into the infarcted myocardium, neonatal ISL1+ cardiac
progenitors had a significantly higher ability to preserve myocardial function, prevent
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adverse remodeling, and enhance blood vessel formation (Simpson et al., 2012). This
suggests that ISL1+ cardiac progenitors derived from the young heart may be more ideal
for cardiovascular regeneration.
In this dissertation we utilize a novel stem cell population characterized by the
expression of both ISL1 and ckit. In humans, this population of cells was thought to only
exist in the fetal heart (Serradifalco et al., 2011), however, we have isolated
cardiovascular stem cells that co-express both ISL1 and ckit from the adult heart (57-75
year olds). Because of the essential role of both ISL1 and ckit in cardiogenesis, the coexpression of these markers could potentially identify a progenitor population with high
regenerative capacity. The fact that this vital population persists throughout life, yet, the
aged heart still has limited regenerative capacity suggests that these cells are either too
few in the adult heart, not activated sufficiently after injury and/or there are underlying
biological differences between adult ISL1+ ckit+ cardiac progenitors and phenotypicallymatched cardiovascular progenitors from the young heart.
In this dissertation we created single cell clones from our newly isolated adult
ISL1+ckit+ cardiovascular progenitors and compared them to similarly isolated and
cloned ISL1+ ckit+ cardiac progenitors from the neonatal (<1month old) heart.
Comparison of single cell clones allows us to define how age impacts epigenetic,
phenotypic, and functional parameters within ISL1+ ckit+ cardiovascular stem cells.
This will provide a better mechanistic understanding of the superior regenerative ability
of neonatal ISL1+ ckit+ cardiac progenitors and will provide novel therapeutic targets to
improve myocardial regeneration.
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In chapter 2, we will address the following hypotheses:
Hypothesis 1: Phenotypically-matched neonatal and adult cardiovascular progenitors
differ in their ability to invade in response to growth factor stimulation and in
their ability to differentiate into endothelial cells and cardiomyocytes.
Hypothesis 2: Superior neonatal functional ability is aided by the expression of
microRNAs which are altered with stem cell age specifically in pathways
influencing cell cycle progression and cellular senescence.
As previously stated, full regeneration of the injured heart may not only require carefully
selected cell types, but will most likely require optimization of cell function by
pretreatment methods. Therefore, in chapter 3, we will address the following hypothesis:
Hypothesis 3: Treatment of neonatal and adult cardiovascular progenitors with shortterm hypoxia and/or prostaglandin E2 (PGE2) will alter MAPK/ERK pathway
activation and increase cardiac progenitor cell cycle progression, migration and
paracrine factor expression.
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Abstract
Although clinical benefit can be achieved after cardiac transplantation of adult ckit+ or cardiosphere-derived cells for myocardial repair, these stem cells lack the
regenerative capacity unique to neonatal cardiovascular stem cells. Unraveling the
molecular basis for this age-related discrepancy in function could potentially transform
cardiovascular stem cell transplantation. In this report, clonal populations of human
neonatal and adult cardiovascular progenitor cells were isolated and characterized,
revealing the existence of a novel subpopulation of endogenous cardiovascular stem cells
that persist throughout life and co-express both c-kit and isl1. Epigenetic profiling
identified 41 microRNAs whose expression was significantly altered with age in
phenotypically-matched clones. These differences were correlated with reduced
proliferation and a limited capacity to invade in response to growth factor stimulation,
despite high levels of growth factor receptor on progenitors isolated from adults. Further
understanding of these differences may provide novel therapeutic targets to enhance
cardiovascular regenerative capacity.
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Introduction
Endogenous cardiac progenitor cells (CPCs) are being carefully investigated to
determine whether they have the ability to repair the heart when expanded in vitro and readministered as a cell-based treatment after myocardial infarction in human clinical trials
(Bolli et al., 2011; Makkar et al., 2012). As CPCs age, however, they lose the ability to
efficiently regenerate damaged heart tissue. Telomerase activity is reduced with
chronological age and an associated decline in the number of functionally-competent
cardiac progenitor cells results in a dramatic loss of growth reserve within the adult heart
(Cesselli et al., 2011; Torella et al., 2004). Functional studies in mice have shown that
neonatal, not adult, c-kit+ cardiac progenitors support post-infarct myogenesis (Jesty et
al., 2012). The molecular basis underlying the enhanced capacity for regeneration that
distinguishes human neonatal cardiovascular progenitor cells from adults has not been
defined.
As a fetus matures into a neonate, several developmental changes impact the
CPC. Lineage tracing studies using embryonic stem cells show that early cardiovascular
progenitors expressing MESP1 differentiate into two separate classes of Nkx2.5+
progenitor populations, one characterized by the expression of Isl1 and another
characterized by the absence of Isl1 (Bondue et al., 2011). The Isl1+ cardiac progenitors
can be differentiated into all three cardiac lineages including endothelial cells, smooth
muscle cells, and cardiomyocytes (Laugwitz et al., 2005). The differentiation capacity of
Isl1- CPCs is limited to smooth muscle cells and cardiomyocytes (Bondue et al., 2011).
Histological analysis suggests that cells positive for Isl1, and SSEA-4 (an early stem cell
marker) are abundant in the fetus and are only sporadically found in the neonate. Cells
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expressing c-kit and Nkx2.5 decline in number significantly as a neonate transitions into
an infant (Amir et al., 2008; Mishra et al., 2011). A gradual reduction of proliferation
occurs in the heart at this time; during the neonatal period there are 3 times as many
proliferating cells as those identified in children >2 years of age (Mishra et al., 2011).
After the first month of life, the dynamics of the CPC population changes dramatically,
highlighting the neonatal window as an optimal time during which progenitor cells can be
isolated for therapy. The biological features that distinguish neonatal cardiovascular
progenitor cells in humans will provide new insight that can be used to improve the
outcome of stem cell-based treatment.
In this report, the epigenetic, phenotypic and functional changes that distinguish
neonatal from adult cardiovascular progenitor cells are detailed within a newly-defined
population of Isl1, c-kit co-expressing cardiovascular progenitor cells. By comparing
matched, clonal cardiovascular progenitor cell populations that differ only by age, we
identify significant differences in microRNA regulation and gene expression that
correlate with functional limitations in the adult cardiovascular progenitor cell
population.

Results
Phenotypic Profiling and Identification of Cardiovascular Progenitor Cell Clones
Isolated from Human Neonates and Adults
The surface marker profile of cardiovascular progenitor cell clones residing
within the heart of human neonates <1 month old and 57-75 year old adults was directly
compared by flow cytometry (Fig. 1, Appendix; Supplementary Table 1). Over 240
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Figure 1. Phenotypic characterization of surface markers on neonatal and adult CPC clones.
CPC clones from human neonates and adults were compared using flow cytometry to
identify the surface phenotype of these cells. Labeling for select markers on representative
CPC are shown in the figure where positive staining above the isotype control is shown in
black. Each column represents a separate and representative clonal population. The
surface phenotype of 24 clones was examined in total.
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cardiovascular cell clones were isolated by single cell expansion. Phenotypic profiling
using seventeen different antibodies (Appendix; supplementary table 2), specific for
surface antigens reported to be present on functionally competent cardiovascular
progenitors, provided a basis for identifying comparable cardiovascular progenitor cells
residing in the heart of both newborns and adults. All clones expressed moderate to high
levels of CD105 (60.6 – 99.8%), CD73 (41.0 – 98.3%), CD44 (60.6 – 99.8%), CD13
(73.7 - 99.9%), IGF1R (58.0 – 99.1%), and CD146 (35.7 – 99.9%). c-kit was expressed
at lower levels (2.5 – 52.4%), and expression of KDR (0 – 75.1%), PDGFR (2.4 –
57.9%), CD34 (4.9 – 78.8%) and SSEA4 (0 –95.7%) was variable, thereby distinguishing
specific populations. Interestingly, the majority of surface antigens were not expressed
at significantly different levels in adult and neonatal cardiac progenitors. Of the 17
surface antigens profiled, only CD31 was expressed at significantly lower levels in adult
cardiovascular progenitors (p=0.04). The progenitors were positive for the expression of
HLA class I antigens (82.6 – 99.9%) and HLA class II antigens were either not expressed
(0 - 3.9% in 21 CPC clones) or expressed at low to moderate levels (3 CPC clones 8.3%,
28.6%, 34.1%).

Coexpression of Isl1 and C-Kit on Human Neonatal and Adult Cardiac Progenitors
Expression of Isl1 and c-kit identifies cells with cardiomyogenic potential
(Ferreira-Martins et al., 2012; Moretti et al., 2006). Characterization by flow cytometry
and PCR revealed that Isl1 and c-kit were co-expressed on CPC clones isolated from both
neonates and adults (Fig. 2). The majority of CPC clones expressed moderate levels of ckit (23 ± 3% in neonates, 27 ± 3% in adults). In neonates, Isl1 was present on most, but
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Figure 2. Co-expression of Isl1 and c-kit on neonatal and adult cardiovascular progenitors.
Adult and neonatal cardiovascular progenitor cell clones were examined by PCR and flow
cytometry to determine whether Isl1 was expressed in these cells. c-kit expression, initially
identified by flow cytometry, was confirmed by PCR. PCR products were run on a gel,
transcripts for Isl1 (size=202bp) and c-kit (size=105bp) were co-expressed on both
neonatal (A) and adult (B) cardiovascular progenitor cell clones. Flow cytometry
confirmed the expression of Isl1 protein (C & D) and the coexpression of Isl1 and c-kit
protein (E) on neonatal and adult cardiovascular progenitors.
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not all kit+ clones (78%, N=13). In adults, cardiac progenitor clones were all c-kit+ and
Isl1+ (N=16).
The Isl1+ c-kit+ neonatal and adult CPC clones were differentiated into
cardiomyocytes using previously reported protocols (Smits et al., 2009). Successful
differentiation was supported by the expression of mRNA transcripts for NK2
homeobox 5, gata binding protein 4, cardiac myosin light chain 2, cardiac myosin heavy
chain alpha and troponin T, which were induced during the differentiation protocol
(N=12, Appendix; Supplementary Fig. 1). There were no significant differences in
transcription of these proteins between neonatal and adult Isl1+ c-kit+ cardiovascular
progenitors. Cardiac progenitor cells were shown by immunocytochemistry to express
cardiac Troponin I (Appendix; Supplementary Fig. 2). When treated with 10nM
dexamethasone for 6 days (D'Amario, Fiorini, et al., 2011), CPCs were successfully
differentiated into all three cardiovascular lineages as demonstrated by a shift in mean
fluorescence intensity when the cells were treated with antibodies to identify binding to
smooth muscle actin, von Willebrand Factor, cardiac Troponin T and cardiac Troponin I
using flow cytometry.

MicroRNA Profiling Predicts Functional Differences in Neonatal and Adult
Cardiovascular Progenitors.
Unique differences in epigenetic regulation emerged when comparing cardiovascular
progenitor cell clones by microRNA profiling. MicroRNAs (miRNAs) function to
negatively regulate mRNA expression by either translational inhibition or degradation.
When comparing neonatal and adult CPC clones, 41 out of 88 microRNAs analyzed were
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Figure 3. MicroRNA profiling and gene expression predicts functional differences when
comparing neonatal and adult cardiovascular progenitors. A) Heat map of 41 microRNAs
differentially regulated in neonatal (N=8) and adult (N=3) cardiac progenitors. hESC were
also profiled as a means for comparison. Red color identifies maximum expression, black
color represents average expression, blue color identifies microRNAs with minimum
expression. Sets of co-regulated microRNAs were grouped together by RT2 Profiler PCR
Array Data Analysis Version 3.5 software (SABiosciences). B) MicroRNAs expressed at
significantly different levels in adult vs. neonatal CPCs suggest that proliferation is higher
in neonatal CPCs. MicroRNA 17, miR-20a, and miR-106b levels, positively correlated
with proliferation, were significantly higher in neonatal CPCs (p=0.0094, p=0.0030,
p=0.0085, respectively). C) MicroRNA-371-3p, associated with senescence, was
expressed at significantly higher levels in adult CPCs (p=0.0238). D) Messenger RNA
transcripts for E2F1 (N=6) and E) Myc (N=5) were significantly higher in adult
cardiovascular progenitors (p=0.0075, p=0.0086 respectively). E2F1 regulates the G1 to
S transition of the cell cycle. F) Expression of DNA repair proteins ATM (N=5) and
RAD50 (N=5) were significantly higher in adult CPCs (P=0.0099, P<0.0001, respectively).
G) Representative cell cycle analysis of neonatal and adult CPCs. H) Quantification of cell
cycle analysis. The frequency of adult CPCs (N=5) in G1 was significantly higher than
neonatal CPCs (P=0.0038). The frequency of neonatal CPCs (N=5) in the S and G2 phases
of the cell cycle was significantly higher than adult CPCs (p=0.0066, p=0.0051
respectively).
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expressed at significantly (P<0.05) different levels (Fig. 3a, Appendix; Supplementary
Table 3). MicroRNA expression levels in hES-3 embryonic stem cells were also
identified and the results are shown in Figure 3 for comparison. The microRNA
expression pattern of neonatal cardiac progenitors was more similar to that of human
embryonic stem cells, highlighting a number of shared characteristics. DIANA mirPath
computational software identified forty-six pathways that were significantly (P<0.05)
impacted by differentially-expressed microRNAs (Appendix; Supplementary Table 4).
Fourteen of these pathways were relevant to proliferation, including Wnt signaling,
MAPK signaling, p53 signaling, TGF-β signaling, VEGF signaling, and base excision
repair. Functional differences in proliferation would be anticipated based on the
expression of microRNAs 17, miR-20a, and miR-106b which were expressed at
significantly higher levels in neonatal cardiovascular progenitors (Fig. 3b) (B. Li et al.,
2011; Petrocca et al., 2008; Pickering, Stadler, & Kowalik, 2009; Trompeter et al., 2011).
High levels of expression of these microRNAs promotes cell cycle progression by
suppressing the inappropriate accumulation of E2F1 transcription factors that lead to G1
arrest (Petrocca et al., 2008; Pickering et al., 2009). E2F1 regulates the G1 to S transition
of the cell cycle to induce proliferation (Wu et al., 2001). The 16-fold reduction in
mRNA transcripts for E2F1 in neonatal cardiac progenitors was confirmed by RT-PCR
(p=0.0075, Fig. 3c).

Replicative Senescence in Adult Cardiac Progenitors Predicted by MicroRNA and
Gene Expression Differences
Replicative senescence is defined by a progressive loss in proliferative ability
despite normal viability and metabolic activity (Morgado-Palacin, Llanos, & Serrano,
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2012) and is associated with an increased DNA damage response and increased cell size
(Rodier & Campisi, 2011). Several microRNAs that were highly expressed in neonatal
CPCs are linked to proliferative ability and play a role in preventing cellular senescence.
MicroRNAs 20a and 17, which were upregulated in neonatal CPCs (27.3 fold, P=0.0030
and 12.5 fold, P=0.0094 Fig. 3b), function to rescue cells from Ras-induced cellular
senescence (L. Li et al., 2012) and reduce DNA double-stranded breaks (Pickering et al.,
2009). In contrast, microRNA-371-3p (Wagner et al., 2008), upregulated 27.9 fold
(p=0.0238) in adult cardiovascular progenitor cells, is induced during replicative
senescence. Myc expression has been associated with the induction of cellular
senescence (Campaner et al., 2010) due to DNA stress (Robinson, Asawachaicharn,
Galloway, & Grandori, 2009). Transcripts for Myc and DNA repair proteins, RAD50
and ATM were significantly elevated in adult cardiac progenitors (2.9 fold, P=0.0086,
28.5 fold, P<0.0001, 35.7 fold, P=0.0099 respectively, Fig. 3c&d). Comparison of cell
size by flow cytometry in three separate experiments using forward scatter gating
demonstrated that adult cardiac progenitors had a greater percentage of large cells when
compared with neonatal CPCs (56.3% vs. 40.2%, N=5, p=0.0073).

Rate of Progression through the Cell Cycle Differs in Neonatal and Adult
Cardiovascular Progenitors
To further investigate the predicted proliferative differences demonstrated by
microRNA profiling, propidium iodide (PI), a DNA intercalating agent, was used to
identify the percentage of cells in each phase of the cell cycle. Using flow cytometry to
detect PI fluorescence intensity, a higher frequency of adult cardiac clones were
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Figure 4 –MicroRNAs expressed at significantly different levels (p<0.05) impact invasion.
MicroRNAs that both promote (A) and inhibit (B) invasion were expressed at significantly
different levels when comparing neonatal and adult CPC by RT-PCR. MicroRNAs that
promote the ability to invade are transcribed at significantly higher levels in neonatal CPCs.
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identified in G1 (82.5% vs. 63.3%, P=0.0046) and a higher frequency of neonatal clones
were identified in S phase (19.4% vs. 7.0%, P=0.0026) and in G2 (15.0% vs. 7.5%,
P=0.0051) (Fig. 3e). Neonatal CPCs proliferate more actively when compared to adult
CPCs.

Cardiovascular Progenitors from Neonates and Adults Differ in Their Ability to
Respond to Growth Factor Stimulation
Cardiac regeneration requires CPC migration away from its stem cell niche,
followed by invasion into the area of injury in response to external stimuli. Nine
microRNAs reported to regulate invasion (Aigner, 2011; Xuwei Hou et al., 2012; Jain et
al., 2012; Ucar et al., 2010) were expressed at significantly (P<0.05) different levels in
neonatal and adult CPCs (Fig. 4). To investigate the possibility that neonatal and adult
progenitors differ in their ability to invade the site of injury within the heart, transwell
invasion assays were performed to test the response of cells to SDF-1α (stromal cellderived factor-1). SDF-1α is secreted in the infarcted heart and recruits endogenous
cardiac stem cells to the site of injury (J. M. Tang et al., 2011; Y. L. Tang et al., 2009).
Fewer adult cardiac progenitors (6.7 x 103) were able to invade through the basement
membrane extract when compared to neonatal CPCs (14.6 x 103, p=0.0463, Fig. 5a). The
inability of adult CPCs to invade in response to SDF-1α was not due to the lack of SDF1α receptor expression on the surface of these CPCs, as demonstrated by flow cytometry.
The surface expression of CXCR4 and CXCR7, both of which are receptors for SDF-1α
(Tarnowski et al., 2010), was comparable on progenitors isolated from neonates and
adults (Fig. 5b).
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Figure 5. Cell invasion in response to SDF-1. A) Phenotypically similar neonatal and adult
clones were run on a transwell invasion assay. The adult CPC clones were less invasive
than their neonatal counterparts (n=5, run in triplicate) in response to SDF-1α, results were
significant to P = 0.0463. B) SDF-1α receptors, CXCR4 and CXCR7, were expressed on
both neonatal and adult cardiovascular progenitor cell clones. Each column represents a
separate and representative clonal population. Isotype control labeling is shown in white,
positive labeling is shown in black.
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SSEA-4+ Cardiovascular Progenitors Invade More Readily
SSEA-4 was not expressed on all CPC clones. Inherent differences were noted in
neonatal and adult cardiac progenitors that were found, by flow cytometry, to express
SSEA-4. MicroRNA profiling revealed 26 microRNAs expressed at significantly
different levels between SSEA4+ adult and neonatal progenitors (P<0.05, Fig. 6A,
Appendix; Supplementary Table 5). The top ten pathways, regulated by these
microRNAs that impact cardiovascular stem cell function are shown in figure 6b. Six of
these pathways impact invasion (marked with an arrow). In functional studies, the
SSEA-4+ progenitors were more highly invasive than SSEA4- clones within the neonatal
cardiovascular progenitor cell population (2.0 x 104 vs 9.1 x 103, p=0.0186, Fig. 6C).
Adult CPC clones expressing SSEA4+ were similarly more responsive to SDF-1 (8.1 x
103 vs 3.9 x 103, p=0.0297). SSEA4+ cardiovascular progenitors display an enhanced
capacity to invade infarcted tissue in response to injury.

Discussion
In the present study, Isl1+ c-kit+ cardiovascular progenitor cells, identified in
both human neonates and adults, were expanded as clonal populations and utilized as a
resource to unravel the phenotypic and epigenetic features that distinguish neonatal and
adult cardiac progenitors.
This population of cells was not previously described within the endogenous
cardiovascular progenitor cell population in adult humans and challenges current dogma
suggesting that Isl1+ CPCs are abundant only in the fetal or neonatal heart (X. Hou et
al., 2012; Simpson et al., 2012). Previous reports comparing neonatal and adult
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Figure 6 – SSEA-4 separates cardiovascular progenitors by the ability to invade. A) Heat
map of 26 microRNAs whose expression was differentially regulated in SSEA4+ neonatal
and adult cardiovascular progenitors (p<0.05). Red color identifies microRNAs with
maximum expression, black color indicates average expression, blue color shows
microRNAs with minimum expression. Sets of similarly expressed microRNAs are
grouped together by RT2 Profiler PCR Array Data Analysis Version 3.5 software
(SABiosciences). B) MicroRNAs expressed at significantly different levels when
comparing SSEA4+ adult and neonatal CPCs were analyzed using DIANA mirPATH
software. The top ten pathways that impact cardiovascular stem cell function, and are
regulated by these microRNAs, are shown. Six of the top ten pathways impact invasion
and are marked with an arrow. The red line denotes significance of P=0.05. C) The
invasive response of SSEA4+ neonatal and adult cardiovascular progenitor cell clones, run
on a transwell migration assay, was compared. Both SSEA4+ neonatal and adult CPCs
were significantly more responsive to SDF-1α when compared to SSEA4- neonatal and
adult CPC, respectively (P=0.0186, P=0.0297).
SSEA4+ neonatal cardiovascular
progenitor cell clones were most responsive to SDF-1. These cells were significantly more
invasive when compared to both SSEA4+ adult and SSEA4- neonatal CPC clones
(p=0.0183, p=0.0186).
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cardiosphere-derived cells (CDCs) for Isl1 expression indicated that Isl1 is abundant in
neonatal CDCs but not in CPCs isolated from adults (36.2% of neonatal CPCs versus
3.2% adult CPCs) (Simpson et al., 2012). Cardiac progenitors co-expressing c-kit and
Isl1, identified in the fetal heart (Serradifalco et al., 2011), have not been isolated from
the adult myocardium. Stem cells isolated from the adult heart were reported to have no
overlap in expression of c-kit and Isl1 (0.01% coexpression by flow cytometry) (ItzhakiAlfia et al., 2009). The very existence of an Isl1+ c-kit+ progenitor in human adults has
been questioned (Sussman, 2012). Our results demonstrate, for the first time, that the
Isl1+ c-kit+ cardiac progenitor phenotype exists in both the neonatal and adult human
heart. As in the embryonic heart (Serradifalco et al., 2011), all progenitors that expressed
Isl1 expressed c-kit, however not all c-kit+ cells expressed Isl1, suggesting that the Isl1+
c-kit+ progenitor may be a subpopulation of c-kit+ progenitors. PDGFR and IGF1R,
which are present on subpopulations of c-kit+ progenitors with superior regenerative
capacity (D'Amario, Cabral-Da-Silva, et al., 2011; Hidaka et al., 2010), were expressed at
moderate to high levels on these cells.
HLA Class II antigens were not expressed on the majority of neonatal and adult
CPC clones. MHC class II expression activates acute T-cell mediated graft rejection
(Pietra, Wiseman, Bolwerk, Rizeq, & Gill, 2000). Allogeneic transplantation of class I
positive, class II negative cardiac progenitors would be expected to elicit a minor, but
transient local immune response (Malliaras et al., 2012).
Based on findings reported here, the capacity for cardiac regeneration after
transplantation of CPCs in neonates and adults is impacted by underlying differences in
epigenetic regulation. Forty-one microRNAs were expressed at significantly different
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levels as a consequence of age. Pathways significantly impacted by these microRNAs
fell into broad categories such as proliferation (ex. p53 signaling, base excision repair,
MAPK signaling) and migration/invasion (ex. Regulation of Actin Cytoskeleton, TGF-β
signaling, VEGF signaling) suggesting that regulatory mechanisms governing these
processes differed significantly in neonatal and adult progenitors. In rodents, microRNA
profiling similarly identified mechanisms by which a proliferative difference occurs when
comparing neonatal and adult CPCs (Sirish et al., 2012). Human embryonic CPCs
directly isolated from the heart without culture have a proliferative advantage over adult
CPCs (Sirish et al., 2012). Our studies take this work a step further by using matched
clonal populations to document distinct differences in microRNA expression when
comparing neonatal and adult human cardiovascular progenitor cells.
A possible mechanism for decreased proliferation in adult cardiac progenitors is
complex regulation of the Myc-E2F1 axis by microRNAs leading to an increase in
cellular senescence. E2F1 is a transcriptional activator that is important in the G1/S
transition; inappropriate accumulation of E2F1 increases DNA damage response and
significantly impacts the ability of cells to enter the S phase of the cell cycle (Pickering et
al., 2009). High levels of Myc expression may result in senescence by initiating cellular
stress (Campaner et al., 2010). This stress leads to upregulation of DNA repair proteins
and cell cycle arrest (Robinson et al., 2009), both of which were observed in adult cardiac
progenitors. MicroRNA-371-3p, which was highly expressed in adult CPCs, is correlated
with induction of senescence (Wagner et al., 2008). Pro-proliferative microRNAs such
as miR-106b, mir-20a, and mir-17 also play a role; these microRNAs help reduce G1
arrest through regulation of E2F1 transcription factors (Pickering et al., 2009; Trompeter

68

et al., 2011). Transcripts for all three microRNAs were significantly elevated in neonatal
CPCs and mir-17 and mir-20a are directly regulated by Myc expression (Coller, Forman,
& Legesse-Miller, 2007; Pickering et al., 2009).
MicroRNA profiling and pathway analysis also predicted differences in the
capacity to invade, results that were confirmed in vitro. Fewer adult CPCs responded to
SDF-1α, despite having adequate CXCR4 and CXCR7 receptor levels on their surface.
SDF-1α is secreted in the damaged heart and recruits both exogenous and endogenous
cardiovascular stem cells to the site of injury (Y. L. Tang et al., 2009). Interestingly, not
all neonatal and adult cardiac progenitors responded equally to SDF-1α; we identified a
subpopulation of neonatal and adult progenitors that expressed SSEA-4. SSEA-4 is a
stem cell marker that identifies cells in early stages of progenitor development
(Henderson et al., 2002). In our study, SSEA-4 expression was correlated with
differential expression of microRNAs involved in invasion-related pathways. SSEA-4 is
expressed on cancer cells that are more highly invasive (Van Slambrouck & Steelant,
2007), however little is known about the impact of SSEA-4 on SDF-1α-induced invasion
in cardiovascular cells. Our study shows that SSEA-4+ progenitors invaded more readily
in response to SDF-1α when compared to their SSEA-4- counterparts. Comparison of
SSEA4+ neonatal and adult CPCs demonstrated that age negatively impacts invasion.
There may be several reasons for this age-related functional discrepancy. SDF-1α
signals primarily through Akt signaling or ERK1/2 signaling. Depending on the cell
type, these pathways can signal independently, one regulating the survival and
proliferation functions of SDF-1 signaling, the other regulating invasion and migration
(Peng et al., 2005). After activation by SDF-1α, CXCR4 dimerizes and is phosphorylated
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by JAK2 and JAK3 which create docking sites for transcription factors to propagate
signaling (Vila-Coro et al., 1999). Adult CPCs may demonstrate decreased CXCR4
dimerization, reduced numbers of cosignaling molecules, or lower levels of
phosphorylation and activation of the receptor. Additionally, the cells themselves may
secrete different levels of growth factors which could contribute to lower levels of
receptor activation.
MicroRNAs play a role in SDF-1α signaling and invasion. Significant differences
in microRNA expression in aged cardiac progenitors influences functional parameters
relevant for cardiovascular repair. For example, activation of the SDF-1α receptor,
CXCR4, induces the expression of proteases such as matrix metallopeptidase 9 (MMP9)
which help to degrade the extracellular matrix, allowing cells to invade (Yu et al., 2011).
The expression of MMP9 is inhibited by miR-132 (Ucar et al., 2010) and miR-206 (H.
Liu, Cao, Ye, & Sun, 2010). The expression of these microRNAs were significantly
upregulated in adult CPCs when compared with their expression level in neonatal CPCs
(6.0 fold, p=0.0005, 9.6 fold, p=0.0166 respectively). Inhibitors of invasion, such as
metallopeptidase inhibitor (TIMP3) (Jain et al., 2012) and homeo box A5 (HOXA5) (X.
H. Liu et al., 2012) are targeted by microRNAs upregulated in neonatal cardiac
progenitors. MicroRNA-103 represses the expression of TIMP-3 (Jain et al., 2012)
(elevated 8.7 fold in neonatal CPCs, p=0.0027) and microRNA-130a represses the
expression of HOXA5 (Chen & Gorski, 2008) (elevated 2.4 fold in neonatal CPCs,
p=0.0288). If adult progenitors cannot effectively invade the site of injury, a dramatic
difference in regeneration will occur with age.
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MicroRNA-mediated regulation of gene expression is a novel, rapidly expanding
area of research which has opened up new therapeutic options for the reversal of heart
disease. Pretreatment of cardiac progenitors prior to transplantation, or direct
administration into the heart may activate stem cell recruitment from endogenous
sources. In neonatal rodents, microRNA mimics had a positive effect on cytokinesis,
DNA synthesis, and cell cycle re-entry (Eulalio et al., 2012). MicroRNAs whose
expression levels are altered in aged CPCs may be manipulated in vivo to promote
recovery from myocardial damage. For example mir-24 (upregulated 8.4 fold in neonatal
CPCs) when introduced after myocardial infarction reduces infarct size (Boregowda et
al., 2012). Conversely, inhibition of mir-208a (upregulated 12.4 fold in adult CPCs)
reduced cardiac remodeling, improved cardiac function, and survival after hypertensioninduced heart failure (Abdelalim & Tooyama, 2012). The potential for microRNA-based
therapeutics to promote stem cell mobilization, combined with an understanding of the
role of microRNAs in cardiac regeneration, promises to open up new treatment options
that may improve the outcome of stem cell-based therapies.
Cardiovascular progenitor cells co-expressing c-kit and Isl1 can be identified and
expanded in vitro from neonatal and adult heart tissue. Epigenetic differences highlight
the mechanism by which neonatal cardiovascular progenitor cells can proliferate and
invade in response to cytokine stimulation, whereas the adult cells have a diminished
capacity for mobilization. Neonatal cardiac progenitor cell clones expressing SSEA-4
are more responsive to stimulation and may be optimal for cardiac regeneration.
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Methods
Ethics Statement/ Cell Isolation and Expansion
The Institutional Review Board of Loma Linda University approved the protocol
for use of tissue that was discarded during cardiovascular surgery, without identifiable
private information, for this study with a waiver of informed consent. Discarded atrial
cardiac tissue from human neonates (<1 month old) and adults (57-75 years old), was cut
into small clumps (approximately 1mm3) and collagenase digested (Roche Applied
Science, Indianapolis, IN) for approximately 2 hours at 37 degrees at a proportion of
1:2.5 tissue volume vs. collagenase. This solution was then passed through a 40μm cell
strainer to isolate cardiac progenitors (Smits et al., 2009). Resulting cells were cloned by
limiting dilution at a concentration of 0.8 cells per well to create clonal populations
which were expanded for further study. Over two hundred and forty clones were isolated
from human patients by this procedure; seventeen neonatal and sixteen adult
cardiovascular cell clones were compared in detail for this study. The human embryonic
stem cell line hES-3 was cultured as previously published (Kearns-Jonker et al., 2012).
Cardiac progenitor cell clones were differentiated both by treatment with 5-azacytidine
followed by ascorbic acid and TGF- β to induce cardiomyogenic differentiation (Smits et
al., 2009) and by treatment with 10nM dexamethasone in DMEM/F12 media
supplemented with 10% fetal bovine serum to induce differentiation into all three
cardiovascular lineages (D'Amario, Fiorini, et al., 2011). Cardiomyogenic differentiation
was confirmed by measuring the induction of mature cardiac-specific transcripts by RTPCR. Expression of endothelial, smooth muscle, and cardiomyocyte markers induced by
dexamethasone treatment were quantified by flow cytometry.
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Flow Cytometry Experiments
Cells were labeled using antibody concentrations that were recommended by the
manufacturer(s). Fluorescently labeled cells were analyzed using a MACSquant analyzer
(Miltenyi Biotec, Auburn, CA). FlowJo software (Ashland, OR) was used for
quantification. Dead cells and small particles were gated out using forward-scatter, sidescatter gating. Isotype controls (MS IgG1) were used to define negative and positive
populations. Antibodies used included CD105-PE, IGF1R-PE, CXCR4-PE, CXCR7-PE,
CD140a-PE, CD146-PE, SSEA-4-FITC, Pan HLA-FITC, CD309-PerCP/Cy5.5
(Biolegend, San Diego, CA), CD44-FITC, CD13-PE, CD31-PE, HLA-Dr-PE, CD73-PE,
CD34-PE (BD Biosciences San Jose, CA), CD90-PE (Immunotech, Brea, CA), CD117PE (Millipore, Billerica, MA). Additional antibody data can be found in appendix;
supplementary table 2. Relative percentage of large neonatal and adult cardiovascular
progenitors was assessed by flow cytometry. Large cells were defined by forward scatter
gating that was uniformly applied to all samples and the percentage of cells within this
gate was compared. Each test was run in duplicate.

RT-PCR
Total RNA was extracted from neonatal and adult cardiovascular progenitor cell
clones and reverse transcribed into cDNA using superscript III (Invitrogen, Grand Island,
NY). Real-time PCR was performed using Go Taq® Green Master Mix (Promega,
Madison, WI). The PCR conditions were: 94°C for 10 minutes, 94°C for 15 seconds,
56°C for 60 seconds, 72°C for 30 seconds for a total of 40 cycles. Human primers were
created using NCBI primer blast and included tyrosine-protein kinase (c-kit),
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and ISL LIM homeobox 1 (Isl1).
Primer sequences are listed in appendix; supplementary table 6.
For microRNA profiling experiments, total RNA was extracted from
representative neonatal (N=8) and adult (N=3) CPC clones and converted to cDNA using
the RT2 miRNA First Strand Kit (SABiosciences, Valencia, CA). The Cell Development
& Differentiation miRNA PCR array plates (SABiosciences, Valencia CA) and RT2
SYBR Green qPCR Mastermix (SABiosciences, Valencia, CA) was used. Plates were
run on an iCycler iQ5 PCR Thermal Cycler (Bio-Rad, Hercules, CA) for 94°C for 10
minutes, 94°C for 15 seconds, 60°C for 60 seconds, 72°C for 30 seconds for a total of 40
cycles. Fold change was calculated using the ΔΔCt method(Rodier & Campisi, 2011).
Data from representative cardiovascular cell clones was analyzed individually, then
pooled within age groups. The microRNA expression data has been deposited in NCBI’s
Gene Expression Omnibus (Edgar, Domrachev, & Lash, 2002) and are accessible through
GEO series accession number GSE49235. miRNAs that were expressed at significantly
different levels when comparing neonatal CPC with adult CPC were analyzed using
DIANA mirPath computational software (Athens, Greece) which performs an enrichment
analysis of multiple microRNA target genes, comparing each set of microRNA targets to
all known KEGG pathways (T. M. Liu et al., 2013).

Cell Cycle Analysis
Cells were trypsinized at 60-80% confluency, counted, and concentrated to 105
cells/0.3ml PBS. Ethanol (0.7ml) was added dropwise to fix the cells. Cells were stored
for at least 1 hour at -20 degrees, washed, incubated at 37 degrees with RNase A
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(0.5mg/ml Invitrogen, Grand Island, NY) and propidium iodide was then added at a final
concentration of 10μg/ml. Samples were run on MACSquant analyzer (Miltenyi BIotec,
Auburn, CA). Cell cycle analysis was done using FlowJo software (Ashland, OR).

Transwell Invasion Assay
Cells were plated in the top well of Costar Transwell plates (8μm pores), coated
with Cultrex™ basement membrane extract (Trevigen, Gaithersburg, MD) mimicking
extracellular matrix. Cells were plated at a density of 100,000 cells per 100μl in starved
medium. Stromal cell-derived factor-1α (SDF-1α, Invitrogen, Grand Island, NY) was
used as a chemoattractant at a concentration of 100ng per ml of M199 plus EGM-2 in the
bottom chamber of a transwell plate. After 24 hours, cells in the bottom wells were
trypsinized and counted using a flow cytometer. The response of neonatal and adult CPC
clones was analyzed individually then pooled by age and subdivided according to the
presence or absence of SSEA-4 expression.

Immunocytochemistry
Neonatal and adult CPC were plated on gelatin coated Lab-Tek II cc2 chamber
slides (Nunc, Rochester, NY) and grown at 37º for 4 days, fixed in 4% paraformaldehyde
and stained using a primary anti-troponin I antibody at 10μg/ml (Millipore #MAB1691,
Billerica, MA) and FITC-conjugated, goat anti-mouse IgG secondary antibody at 2μg/ml
(Southern Biotech, Birmingham, Alabama). Coverslips were mounted using Prolong
Gold antifade with DAPI (Invitrogen, Grand Island, NY). Slides were imaged using a
Zeiss confocal LSM 710 NLO laser-scanning, confocal microscope (GmbH, Germany).
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Statistics
RT2 Profiler PCR Array Data Analysis software (SABiosciences, version 3.5) was
used to calculate statistical significance for microRNA profiling. Data was tested for
normal distribution using the Anderson-Darling normality test calculator Version 6.0
with an alpha of 0.05 (faculty.missouri.edu/~glaserr/3700s11/AD-Test_Calculator.xls).
For normally distributed data, an unpaired, two-tailed student's t test was performed. For
data that was not normally distributed, a Mann-Whitney Rank Sum Test was performed.
Statistically significant differences were identified as P < 0.05. Data was reported as the
mean +/- standard error.
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CHAPTER THREE
INVESTIGATION OF A NOVEL THERAPEUTIC STRATEGY TO IMPROVE
ENDOGENOUS CARDIAC STEM CELL FUNCTION

Introduction
The ERK signaling pathway is the classical mitogen-activated protein kinase
signaling pathway that is stimulated by a variety of growth factors including SDF-1α (Hu
et al., 2007; Yin et al., 2011). Changes in the phosphorylation of ERK can have
functional consequences on cell proliferation, invasion, and secretory phenotype (Howe,
Aplin, & Juliano, 2002; H. J. Lee, Cho, Kwon, Park, & Kim, 2013; Xie et al., 2014).
ERK signaling is required for cardiosphere formation and subsequent VEGF production,
and inhibition of ERK results in increased levels of stemness associated genes such as
OCT4 (Cho et al., 2012). Tight regulation of the ERK signaling pathway in CPCs is
essential, as small increases in phosphorylation can result in functional benefits whereas
large increases in ERK phosphorylation are associated with replicative senescence (Choi
et al., 2013). Duration and intensity of ERK phosphorylation can also impact
downstream functional consequences (Murphy & Blenis, 2006).
In this chapter we investigated the potential for a novel combination of short-term
hypoxia and prostaglandin E2 treatment to improve endogenous CPC function through
regulation of the MAPK/ERK signaling pathway. There is evidence that treatment of
with a combination of hypoxia and PGE2 can result in additive functional improvements
(Jung, Choi, Yoo, Baek, & Kwon, 2013) through overlapping signaling. In human cancer
cells, 24 hours of hypoxia (1% oxygen) activated the cyclooxygenase-2-PGE2 synthase
axis (J. J. Lee et al., 2010). Conversely, treatment with PGE2 induced hypoxia-inducible
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factor-1α (HIF-1α) stabilization and nuclear localization (X. H. Liu et al., 2002). In
endothelial cells, exogenous administration of PGE2 augmented hypoxia-induced
proliferation and VEGF secretion (Zhao et al., 2012) and in hematopoietic stem cells,
increased HIF-1α was required for increased migration through PGE2 mediated
upregulation of CXCR4 (Speth, Hoggatt, Singh, & Pelus, 2014). Both migration and
invasion are important CPC functions required for cardiac regeneration. In response to
external stimuli, cardiac progenitors must first migrate through the blood and
extracellular fluid towards the site of injury. Once at the site of injury, CPC must then
invade, through the use of proteases and other proteins and infiltrate the injured area. In
this chapter, we report the response of neonatal and adult cardiovascular progenitors
treated with short-term hypoxia and prostaglandin E2. We measured the relative
phosphorylation of ERK and the functional consequences of altered signaling after cell
treatment, specifically, cell cycle progression, expression of paracrine factors, and
migration.
The portion of this work that was prepared for publication is included in this
chapter. The data summarizing the treatment of cells with hypoxia alone and treatment
of cells with a combination of hypoxia and prostaglandin E2 is included in the appendix.
In brief, exposure to hypoxia (1% oxygen) increased the phosphorylation of ERK
(Appendix, supplementary figure 3) and combination of prostaglandin E2 with hypoxia
further increased the phosphorylation of ERK (Appendix, supplementary figure 4).
Migration, which was not altered by hypoxia exposure, was increased with a combination
of prostaglandin E2 and hypoxia when compared with untreated cells (9803 vs 1987 cells,
p=0.07, appendix, supplementary figure 5). Cell cycle progression, on the other hand was
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not significantly altered by either hypoxia treatment alone or a combination of hypoxia
and prostaglandin E2 (Appendix, supplementary figure 6). Therefore, the combination of
prostaglandin E2 with hypoxia can increase CPC ERK phosphorylation and migration
when compared with hypoxia treatment alone.
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Abstract
Prostaglandin E2 improves functional outcome when injected into the heart or cotransplanted with stem cells after a myocardial infarction. This effect may be mediated
through activation of select populations of existing stem cells.

The signaling and

functional events associated with treatment of human endogenous cardiac stem cells with
prostaglandin E2 is unknown. In this report we used clonal populations of Islet-1+ c-kit+
cardiac stem cells that were derived from the human heart to study the effect of
prostaglandin E2 on migration, cell cycle progression, gene expression and signaling.
Islet-1+ c-kit+ cardiac progenitors expressed transcripts for prostaglandin receptors EP1,
EP2, and EP4 but not EP3 by PCR. A significant increase in migration of cardiac
progenitors was identified after 24 hours of prostaglandin E2 treatment, using a transwell
migration assay. On the other hand, cell cycle progression (as measured by flow
cytometry) was unchanged and differentiation along the cardiac specific lineage as
identified by transcripts for troponin T and myosin light chain 2v was not significantly
induced by a short term exposure to prostaglandin E2. Transcripts for genes encoding
paracrine factors that play a key role in cardiac stem cell regenerative ability, including
insulin-like growth factor 1, stromal cell-derived factor 1α, and vascular endothelial
growth factor A, were expressed at significantly lower levels in endogenous cardiac
progenitors following prostaglandin E2 treatment. Phosphorylation of ERK and the
prosurvival protein, AKT, was also reduced. Our studies show that prostaglandin E2
treatment for 24 hours improves Islet-1, c-kit+ progenitor cell migration but reduces
cytokine expression and the activation of key pathways involved in cardiac stem cell
regenerative ability.
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Introduction
The inability of the adult human heart to completely repair itself after injury, and
the growing number of patients with heart disease, has fueled the investigation of stem
cell-based therapeutics to enhance cardiac regeneration. Recent clinical trials using
endogenous cardiac stem cells administered after myocardial infarction have
demonstrated some benefit following transplantation, however outcomes are varied and
do not completely ameliorate dysfunction (Bolli et al., 2012; Malliaras et al., 2014). Pretreating stem cells prior to transplantation can lead to increased cardiac regeneration after
myocardial infarction (Hahn et al., 2008; Li et al., 2010) and several approaches have
been taken to optimize stem cell function in vitro. One concept is to harness the innate
response to injury as a means of developing new methods that may further enhance
regeneration. For example, in response to cellular injury such as myocardial infarction,
prostaglandin E2 is secreted within the infarct zone. Prostaglandin E2 (PGE2) is a lipid
compound derived from arachidonic acid through a reaction catalyzed by COX-2.
Although prostaglandin E2 is immunomodulatory (Dhingra et al., 2013; Kalinski, 2012)
and has been shown to promote tolerance when co-transplanted with stem cells into the
heart (Dhingra et al., 2013), there is evidence that it may also facilitate cardiac repair
(Xiao et al., 2004). After myocardial infarction, injection of prostaglandin E2 increases
the number of cardiomyocytes in the border zone (Hsueh, Wu, Yu, Wu, & Hsieh, 2014),
whereas knockout of prostaglandin receptor EP4 increases infarct size (Xiao et al., 2004)
and microsomal deletion of prostaglandin E2 synthase-1 impairs restoration of left
ventricular systolic and diastolic function (Degousee et al., 2008). Prostaglandin E2,
therefore, is crucial to repair and may play a role in activating endogenous stem cells.
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We hypothesized that pretreatment of cardiac stem cells with PGE2 prior to
transplantation may enhance their regenerative capacity.
We have previously identified an early cardiovascular progenitor cell population
that can be isolated from the human heart and expresses both the early stem cell marker
Islet-1 (Isl-1) as well as tyrosine protein kinase, c-kit (Fuentes et al., 2013). In this
report, we characterized the effect of prostaglandin E2 on gene expression, signaling, cell
cycle progression and migration in clonal populations of human Isl-1+c-kit+ cardiac
progenitor cells (CPCs).

Materials and Methods
Ethics Statement/Cell Isolation and Expansion
The Institutional Review Board of Loma Linda University approved the protocol
for use of tissue that was discarded during cardiovascular surgery, without identifiable
private information, for this study with a waiver of informed consent. All experiments
were performed according to the principles expressed in the Declaration of Helsinki.
Discarded cardiac tissue from the right atrium was cut into ~1mm3 clumps then incubated
at 37oC for 2 hours with collagenase (Roche Applied Science, Indianapolis, IN). This
solution was then passed through a 40µM cell strainer to isolate cardiac progenitors
(Smits et al., 2009). To create clonal populations for further study, cells were grown at a
concentration of 0.8 cells/well and expanded for further study.

Prostaglandin E2 Dilution
Lyophilized prostaglandin E2 (Cayman Chemical, Ann Arbor, MI) was dissolved
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in DMSO at a concentration of 10mM and stored at -20oC. Prior to adding PGE2 to cell
culture medium, the pH of the media was adjusted to approximately 6.8-7.0.

Cell Cycle Progression
To investigate relative cell cycle progression, cells were treated for 24 hours with
normal growth medium supplemented with 10µM PGE2. After 24 hours, cells were
trypsinized and counted. One hundred thousand cells were fixed in 70% ethanol,
incubated at 37oC with RNAse A (0.2mg/ml, Fisher Scientific Pittsburg, PA), then
labeled with propidium iodide. Stained samples were run on a MACSquant analyzer
(Miltenyi Biotec, Auburn, CA) and analyzed using Flowjo software.

Flow Cytometry
We used flow cytometry to measure phosphorylated proteins. Quantitation of
phosphorylated proteins by flow cytometry is consistent with data obtained by the more
conventional western blot technique and has the added advantage of being able to assess
phosphorylation levels on single cells (Abrahamsen & Lorens, 2013; Jun, Lee, Song,
Mansfield, & Chou, 2011; Krutzik & Nolan, 2003). This technique can also determine
whether or not the level of response is homogenous within the population (Krutzik, Irish,
Nolan, & Perez, 2004). Cardiovascular progenitor cell clones were grown for 24 hours in
starving medium then treated with 10µM PGE2 for 15 minutes. Following treatment,
cells were trypsinized, fixed with 4% paraformaldehyde, permeabilized with 90%
methanol, and labeled with antibodies against phosphorylated ERK 1/2 (Thr202/Tyr204,
Cell Signaling Technology, Danvers, MA) at a 1/200 dilution or pAKT (Ser473, Cell

90

Signaling Technology, Danvers, MA) at a 1/100 dilution. FITC-labeled goat anti-rabbit
IgG (BD Biosciences San Jose, CA) at a dilution of 1/150 was used as a secondary
antibody. After antibody incubation, cells were analyzed using MACSquant analyzer
(Miltenyi Biotec, Auburn, CA). Small particles and dead cells were gated out using
forward-scatter, side-scatter gating. FlowJo software (Ashland, OR) was used for
quantification.

Migration
Migration experiments were performed after CPCs were grown in normal growth
medium supplemented with 10µM PGE2 for 24 hours. Cardiac progenitors were then
trypsinized, counted and plated at a density of 50,000 cells per well in a 96 well transwell
migration assay with 8 micron pores (Corning, Union City, CA). Migration experiments
were performed according to manufacturer’s instructions. In brief, CPCs were
resuspended in starving medium and plated in the top chamber. Normal growth medium
supplemented with 100ng/mL of SDF-1α (Life Technologies, Grand Island, NY) was
used as a chemoattractant in the bottom chamber. After 6 hours, migrated cells in the
bottom chamber were stained using Calcein AM (Fisher Scientific Pittsburg, PA) and
fluorescence was measured using a FLX800 fluorescent plate reader (Bio-Tek, Winooski,
VT). Fluorescence was converted to cell number using a standard curve as per
manufacturer’s instructions.

Quantitative RT-PCR
Trizol reagent (Life Technologies, Grand Island, NY) was used to store cells after
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PGE2 treatment (10µM for 24 hours). RNA was isolated using the RNeasy Mini-spin
Columns (Qiagen, Valencia, CA) and 500ng of RNA was used to make cDNA using the
Superscript III protocol (Life Technologies, Grand Island, NY). Beta actin was used as a
housekeeping control. RT-PCR was run on an IQ5 machine (Bio-rad, Hercules, CA).
The PCR conditions were: 94°C for 10 minutes, 94°C for 15 seconds, 56°C for 60
seconds, 72°C for 30 seconds for a total of 45 cycles or 94°C for 10 minutes, 94°C for 15
seconds, 55°C for 60 seconds, 72°C for 30 seconds for a total of 45 cycles. Primer
sequences can be found in appendix, supplementary table 7. Fold change was derived
using the ∆∆Ct Method (Schmittgen & Livak, 2008).

Statistics
A paired student’s t test was used to calculate significance in cell cycle,
migration, and flow cytometry experiments. A student’s t test was used for RT-PCR
experiments. Significance was set at p<0.05. Data is represented as the mean +/- the
standard error.

Results and Discussion
The vital role of prostaglandin E2 in heart regeneration (Degousee et al., 2008;
Hsueh et al., 2014; Xiao et al., 2004) lends credence to the idea that PGE2 can activate
the human cardiac progenitor population. However, this has not been thoroughly
investigated. It is unknown whether the majority of benefits after prostaglandin E2
administration are mediated through direct activation of existing stem cells within the
heart, or are mediated through other cell types. In this study, we used clonal populations
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Fig. 7. Cell cycle progression after 24 hour treatment of cardiac progenitors with 10µM
PGE2. A) Representative histogram of cell cycle progression in a cardiac progenitor cell
clone. B) Quantification of cell cycle analysis. There was no significant difference in the
cell cycle progression in cardiac progenitor cell clones (n=4) after 24 hours of 10µM PGE2
treatment.
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of human endogenous cardiac progenitors that co-express both c-kit and Isl-1 to elucidate
whether PGE2 could be used as a pretreatment to improve CPC function. The use of
single cell clones with a clearly defined phenotype (Fuentes et al., 2013) allows us to
correlate functional response after PGE2 exposure to a single cell type that normally
resides within the heart.
Methods to promote efficient cardiac regeneration will ideally optimize functions
such as cell proliferation and migration. The ability of stem cells to effectively divide
and repopulate damaged tissue is key to their capacity for cardiac repair. We measured
the effect of PGE2 treatment on proliferation of Isl-1+c-kit+ cardiac progenitors using a
flow cytometry-based approach. After 24 hours, 10µM PGE2 treatment did not alter the
percentage of dividing cells. There was no significant change in the frequency of cells in
G1, S, or G2 phase of the cell cycle (n=4, Fig. 7). This outcome is consistent with results
from other studies using other cell types, such as neuroectodermal stem cells that do not
demonstrate changes in cell proliferation after PGE2 treatment (Wong, Ahmad, Li, &
Crawford, 2014). By and large, the cellular response to PGE2 appears to be dependent on
variables that include cell source, cell type and dose of PGE2. In certain populations of
mesenchymal stem cells, treatment with 10µM of PGE2 for 24 hours increases
proliferation (Jang et al., 2012). In other cell types, proliferation is inversely related to
dose, high doses of prostaglandin E2 decreases proliferation and low doses increases
proliferation (Kleiveland, Kassem, & Lea, 2008; Zhang & Wang, 2014). It is important
to note that cell cycle progression, although unchanged, was not adversely affected by
prostaglandin E2 treatment.
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Fig. 8. Migration after PGE2 treatment in cardiac progenitor cell clones. Treatment with
10µM PGE2 significantly altered cardiac progenitor cell migration after 24hrs (n=4,
p=0.049) but not after 6 hours (n=4, p=0.32).
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Migration is also key to regeneration. After injury, cardiac progenitors must
migrate away from the stem cell niche towards the site of injury. One of the factors that
can induce CPC migration after myocardial infarction is SDF-1α (J. M. Tang et al.,
2011). Previously, we have demonstrated that Isl-1+c-kit+ cardiac progenitor cell clones
have ample expression of the SDF-1α receptor responsible for cell migration, CXCR4
(Fuentes et al., 2013). We therefore tested the effect of prostaglandin E2 on migration of
human Isl-1+c-kit+ cardiac stem cells in response to normal growth medium
supplemented with SDF-1α. We compared the effect of both a 6 hour, and a 24 hour
treatment with 10µM PGE2. As with other cell types (Hoggatt, Singh, Sampath, & Pelus,
2009; X. H. Liu et al., 2002; Speth et al., 2014; Weller et al., 2007), prostaglandin E2
significantly increased SDF-1α-induced migration of Isl-1+c-kit+ cardiac stem cells after
24 hours (9.7x103 cells, PGE2-treated CPCs vs 6.7x103 cells, untreated CPCs, n=4,
p=0.049, Fig. 8). A six hour treatment, however, did not alter cell migration (6.1x103
cells, PGE2-treated CPCs vs 5.5x103 cells, untreated CPCs, n=4, p=0.32, Fig. 8),
suggesting that time may be a factor in stem cell activation. The increased chemotaxis of
CPCs after PGE2 treatment may explain the elevated expression levels of stem cell
markers (noted by others) within the heart after prostaglandin E2 injection in mice (Hsueh
et al., 2014). This suggests that prostaglandin E2 may play a role in homing resident
cardiac stem cells to the site of injury and could hypothetically be used as a pretreatment
to increase cell migration.
There are four receptors for prostaglandin E2 including EP1, EP2, EP3, and EP4.
In mice, EP4 is the most abundantly expressed prostaglandin receptor within the heart
(Xiao et al., 2004). Previous reports have demonstrated expression of all four
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Fig. 9. Expression of prostaglandin E2 receptors by PCR. Cardiac progenitor cell clones
were examined by PCR to determine whether they expressed prostaglandin E2 receptors.
PCR products were run on a gel. Transcripts for EP1 (size = 323bp) EP2 (size = 327bp)
and EP4 (size = 464bp) were expressed on cardiac progenitor cell clones. EP3 (size = 384
bp) transcript expression was not found.
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prostaglandin E2 receptors on other human stem cell types such as mesenchymal (Jang et
al., 2012) and hematopoietic stem cells (Hoggatt et al., 2009), however whether resident
human cardiac progenitors express receptors for prostaglandin E2 is unknown. We
therefore measured transcripts for the four prostaglandin receptors by PCR. Isl-1+ c-kit+
cardiac progenitors expressed transcripts for EP1 (product size 323bp), EP2 (product size
327bp), and EP4 (product size 464bp). EP3 (product size 384bp), however, was not
expressed in any of the CPC clones tested (Fig. 9).

This suggests that the response of

human CPCs to prostaglandin E2 is possibly mediated through signaling in one or more
of the prostaglandin receptors including EP1, EP2, and EP4, but not likely EP3.
Enhanced migration in cardiac progenitors after prostaglandin E2 treatment could
involve signaling in the PI3K-AKT pathway (Guo et al., 2014). Prostaglandin E2
treatment (in cancer cells, tendon stem cells, and dendritic cells) can increase PI3K-AKT
signaling as evidenced by increased levels of phosphorylated AKT (George, Sturmoski,
Anant, & Houchen, 2007; J. Liu, Chen, Tao, & Tang, 2013; Vassiliou, Sharma, Jing,
Sheibanie, & Ganea, 2004). In this study, we quantified the activation of the PI3K-AKT
signaling pathway after prostaglandin E2 treatment by measuring the level of
phosphorylated AKT by flow cytometry. Surprisingly, treatment with 15 minutes of
10µM PGE2, which can increase AKT phosphorylation in other cell types (Buchanan et
al., 2006; Wang & Klein, 2007), decreased AKT phosphorylation levels in CPCs (3968
MFU decrease, n=6, p=0.056, Fig. 10A&C). This suggests that increased migration after
PGE2 treatment in endogenous CPCs, is likely independent of PI3k-AKT signaling. This
decrease in phosphorylated AKT could hypothetically impact functions such as cell
survival (Liou et al., 2007; Vassiliou et al., 2004).
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Fig. 10. Changes in ERK and AKT phosphorylation after PGE2 treatment in starved
medium. Representative histograms displaying A) phosphorylated AKT and B)
phosphorylated ERK protein expression levels by flow cytometry after 15 minutes of PGE2
treatment. C) Levels of phosphorylated AKT were decreased by PGE2 treatment but not
significantly (n=6, p=0.056). D) Levels of phosphorylated ERK were significantly
decreased after prostaglandin E2 treatment in cardiac progenitors (n=6, p=0.035).
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At the present time, stem cell survival after transplantation has been reported to be
relatively low to negligible on a long-term basis (K. U. Hong et al., 2014; Malliaras et al.,
2013). Due to this fact, paracrine mechanisms (rather than direct differentiation), have
been reported to account for the majority of the beneficial effects of cardiac stem cell
transplantation (Chimenti et al., 2010; Kyung U Hong et al., 2014). In other types of
resident cardiac stem cells, the MAPK/ERK pathway regulates the secretion of beneficial
paracrine factors (H. J. Lee et al., 2013). When cardiac stem cells are in ERK-stimulating
conditions, growth factors, such as VEGF, are secreted at elevated levels, whereas in
ERK-inhibitory conditions, cells are more prone to cardiomyogenic differentiation (H. J.
Lee et al., 2013). The MAPK/ERK signaling pathway, if altered, can also affect cell
proliferation, migration, stemness and secretory phenotype (Cho et al., 2012; H. J. Lee et
al., 2013; Ryu et al., 2010; Xie et al., 2014). We measured changes in the MAPK/ERK
signaling pathway by quantifying the level of phosphorylated ERK (pERK) by flow
cytometry. After 15 minutes of exposure to 10µM PGE2, the level of pERK declined
significantly (19,406 MFU decrease, n=6, p=0.035, Fig. 10B&D). This same time frame
increases ERK phosphorylation in other cell types (Krysan et al., 2005; Rao et al., 2007).
Under “ERK-inhibitory” conditions (H. J. Lee et al., 2013) we would expect
decreased growth factor expression. After prostaglandin E2 exposure we used RT-PCR
to quantify the expression of paracrine factors in Isl-1+c-kit+ cardiac progenitors. These
growth factors included hepatocyte growth factor (HGF), insulin-like growth factor 1
(IGF-1), stromal cell-derived factor 1α (SDF-1α), and vascular endothelial growth factor
A (VEGFA) which are all known to improve cell function and enhance cardiac
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Fig. 11. Expression of growth factors in cardiac progenitor cell clones after PGE2
treatment. After 24 hours of 10µM PGE2, the expression of SDF-1, IGF1, and VEGFA
were significantly downregulated in cardiac progenitor cell clones as shown by RT-PCR
(n=3, run in triplicate, p<0.05).
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regeneration after injury (Cheng et al., 2014; Hu et al., 2007; Linke et al., 2005; J. Tang
et al., 2009). As expected (based on ERK phosphorylation levels), 24 hours of
prostaglandin E2 treatment significantly decreased the expression of transcripts for SDF1α, IGF1, and VEGFA (2.3 fold, 7.4 fold, and 9.5 fold respectively, p<0.0000001, Fig.
11). This decline in growth factor expression levels is a novel finding that is inconsistent
with reports in other cell types (Jang et al., 2012; Junpeng Liu, Chen, Liu, & Tang, 2014;
Peng et al., 2013; Zhao et al., 2012) and raises the possibility that prostaglandin E2
treatment, in Isl-1+c-kit+ cardiac stem cells, may hinder their therapeutic efficacy after
transplantation and consequently their regenerative capacity.
In this study, prostaglandin E2 treatment lowered both the phosphorylation level
of ERK and the expression of transcripts for SDF-1α, IGF-1, and VEGFA. We therefore
also measured the effect of PGE2 on the expression of cardiac specific transcripts,
Troponin T and MLC2v. After 24 hours of 10µM PGE2, we identified a trend (less than
2-fold) towards increased expression levels of Troponin T and MLC2v that was not
found to be significant when compared with untreated cells (Fig. 12, n=3, run in
triplicate). This suggests that 24 hours is not sufficient to significantly upregulate
cardiac-specific transcripts associated with cardiomyogenic differentiation.

Conclusions
In this report, we evaluated the effect of prostaglandin E2 on Isl-1+c-kit+ cardiac
progenitors derived from the human heart. Although prostaglandin E2 is a crucial factor
involved in cardiac regeneration (Degousee et al., 2008; Hsueh et al., 2014; Xiao et al.,
2004), at the current doses it is not a preferable pretreatment option for CPCs. Resident
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Fig. 12. Cardiac differentiation in CPCs after PGE2 treatment. RT-PCR expression levels
of cardiac-specific differentiation transcripts, cardiac troponin T (Trop T) and myosin light
chain 2 (MLC2v), were not significantly altered after 24 hours of 10µM PGE2 treatment in
cardiac progenitor cell clones (n=3, run in triplicate).
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cardiac stem cells show enhanced cell migration after exposure to 10µM prostaglandin
E2, however paracrine factor expression declines. Likewise, the phosphorylation of ERK
and AKT, key proteins involved in cell function and survival were decreased in CPCs
after short-term prostaglandin E2 treatment.
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CHAPTER FOUR
CONCLUSIONS & FUTURE DIRECTIONS

Summary
The purpose of this dissertation was to define key epigenetic, phenotypic, and
functional changes that distinguish neonatal and adult cardiovascular progenitors. In
chapter 2, we determined that cardiac progenitors isolated from the adult human heart
have a clear shift in microRNA expression profile with 41 significantly altered
microRNAs. These epigenetic differences may contribute to functional disparities
evident between neonatal and adult cardiac progenitors including significantly decreased
cell cycle progression and reduced SDF-1α-induced cell invasion in adult cardiac
progenitors. Interestingly, both neonatal and adult CPCs had similar cardiomyogenic
differentiation ability as assessed by the expression of cardiac-specific transcripts during
5-azacytidine induced cardiac differentiation by RT-PCR. This change in cardiac stem
cell functional ability is consistent with studies that have determined that neonatal CPCs
have a higher regenerative ability in vivo when compared with adult CPCs (Simpson et
al., 2012). We also distinguished a subpopulation of cardiac progenitors that express
SSEA4, which have superior ability to invade in response to growth factor simulation.
In chapter 3, our goal was to investigate a novel strategy to improve cardiac
progenitor cell function that could serve as a potential pre-treatment of cardiac
progenitors prior to transplantation into the heart after injury. To this end, we assessed
the effect of a combination of hypoxia and prostaglandin E2 on CPC function. The
treatment of CPC with hypoxia for 48 hours followed by an acclimatization period of
normal culture conditions for 6 hours and then 6 hours of 10µM prostaglandin E2 did
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increase ERK phosphorylation and migration when compared with untreated CPCs and
CPCs treated with hypoxia alone. However, treatment of CPCs with hypoxia (when
administered alone) and the combination of hypoxia with prostaglandin E2 did not
significantly alter cell cycle progression.
In this chapter we were also able to elucidate novel changes in CPC function in
response to prostaglandin E2. Although PGE2 treatment can benefit the heart in vivo, it
may not uniformly improve cardiac stem cell function in vitro. We identified that CPCs
expressed three of the four prostaglandin E2 receptors including EP1, EP2, and EP4 by
PCR. Twenty-four hours of 10µM PGE2 treatment significantly increased cell migration,
but decreased the expression of paracrine factors that play important roles in myocardial
regeneration. Furthermore, short-term treatment with prostaglandin E2 decreased the
phosphorylation of AKT and ERK, key signaling molecules involved in stem cell
regenerative ability.

Future Directions
At the end of this work, we are left with several important questions that may
serve as building blocks for future studies. Our long-term goals are to define the
mechanisms that contribute to cardiac stem cell-mediated myocardial regeneration and to
optimize cardiac stem cell functional ability.
The significant change in microRNA expression profile with age lends credence
to the idea that the packaging and secretion of expressed microRNAs is also affected in
aged CPCs. MicroRNAs can act as paracrine factors by being packaged and secreted
within small membrane vesicles of endocytic origin known as exosomes (Théry,
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Zitvogel, & Amigorena, 2002). However, it is unknown whether age influences the level
of exosomes secreted by cardiac stem cells, and secondly whether age can alter the type
and levels microRNAs packaged within exosomes. To test this, we will first isolate
exosomes and validate isolation by western blot marker CD63 as well as confirmation of
relative size of isolated particles. We will then be able to compare relative secretion
levels of neonatal and adult cardiac progenitors, isolate microRNAs from exosomes
(Moldovan, Batte, Wang, Wisler, & Piper, 2013), and determine the relative profile of
microRNAs within exosomes derived from the neonatal and adult CPC conditioned
medium. Lastly, the relative ability of exosomes derived from neonatal and adult CPC to
regulate gene expression and resistance to cell death in cardiomyocytes will be measured
in vitro. This will provide novel information regarding the shift in microRNA expression
within exosomes with age in CPCs, and will allow us to correlate this shift in microRNA
expression with functional differences in cardiomyocytes after exosome treatment in
vitro.
Exosomes can act as critical agents in cardiac regeneration (Chen et al., 2013);
transplantation of CDC-derived exosomes into injured mouse hearts recapitulates the
regenerative and functional effects produced by CDC transplantation, and this effect is
partially mediated by the microRNAs packaged within them (Ibrahim, Cheng, & Marban,
2014). In our work, and work from other laboratories, we have demonstrated the superior
functional capacity of cardiac stem cells derived from the neonatal heart when compared
with cardiac stem cells from the adult heart (Fuentes et al., 2013; Simpson et al., 2012).
It is unknown, however, whether exosomes secreted from neonatal CPCs have a superior
ability to ameliorate cardiac injury when compared with exosomes from adult CPCs. To
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evaluate this we could isolate exosomes from human neonatal and adult CPC conditioned
medium and compare their therapeutic efficacy in a mouse model of myocardial
infarction by intramyocardial delivery of conditioned medium-derived exosomes. Thirty
days after exosome administration, relative infarct size and viable tissue as well as the
level of apoptosis within the heart could be used to determine relative regenerative
efficacy.
The response of cardiovascular progenitors to prostaglandin E2 treatment outlined
in chapter 3 in light of the overwhelming evidence of benefits of prostaglandin E2 in
cardiac injury (Hsueh, Wu, Yu, Wu, & Hsieh, 2014) leaves the question as to the
mechanisms responsible for this disparity in effect. It is known, in other types of stem
cells, that PGE2 can have a biphasic effect with opposing responses at low and high doses
(Kleiveland, Kassem, & Lea, 2008; Zhang & Wang, 2014). Although, in our study, we
did not see uniformly beneficial effects of prostaglandin E2 treatment, this could be due
to dose, duration of treatment, and receptor levels. There are four known receptors for
prostaglandin E2 including EP1, EP2, EP3, and EP4. Interestingly, PGE2 treatment can
regulate the abundance of its own receptors (Jang et al., 2012). Therefore future work
could contrast the effect of low and high doses of prostaglandin E2 on cardiac progenitor
cell function, and evaluate the receptors responsible for functional changes.
After low and high doses of PGE2 we would assess the relative level of EP1-4
receptors and correlate receptor levels to changes in functional parameters such as cell
stemness, cell differentiation, as well as cell cycle progression, migration, and growth
factor expression. To further define the mechanism by which differing doses of PGE2
mediates its effect on CPCs, we would use specific receptor blockers (Sugimoto &
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Narumiya, 2007) for the EP receptors to assess which receptors are responsible for select
cardiac progenitor cell responses to PGE2. We would also assess downstream signaling
transcripts associated with a given receptor to pinpoint the signaling responsible for the
differing effects. This approach would further define the mechanism by which dose and
PGE2 receptor levels govern CPC response to PGE2 treatment.

Conclusions
At the conclusion of this work, we have a better understanding of some of the
various mechanisms underlying superior neonatal regenerative ability and have identified
novel targets for improving adult CPC function. We have established that, with age,
there is a shift in human CPC microRNA expression profile which correlates with
functional differences between neonatal and adult CPCs in vitro. We have also evaluated
a novel combination of prostaglandin E2 and hypoxia and identified changes in CPC
function in response to PGE2 treatment including significantly reduced growth factor
expression, and reduced signaling that may hinder CPC therapeutic efficacy.
The work outlined in this dissertation provides important advancements to the
field of cardiac stem cell mediated regeneration, and provides insight into novel
therapeutic targets and strategies to help repair the damaged heart.
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Supplementary Figure 3 Changes in ERK phosphorylation after time course of cardiac
progenitor cell exposure to 1% O2.

Cardiac progenitors were exposed to 6 hours (n=7), 24 hours (n=3), and 48 hours (n=8) of
hypoxia (1% O2) and ERK phosphorylation was measured by flow cytometry. The mean
fluorescence shift above secondary antibody alone is shown above. Levels of ERK
phosphorylation in response to hypoxia were only significantly elevated in cardiac
progenitors after 48 hours of hypoxia (3423 vs 2683 MFU, p=0.03).
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Supplementary Figure 4 ERK phosphorylation after combination of Prostaglandin E2
and hypoxia treatment.

Cardiac progenitors were treated with 48 hours of 1% oxygen then 6 hours of normal
growth medium (GM) followed by 6 hours of 10µM PGE2. Flow cytometry was used to
measure ERK phosphorylation, mean fluorescence shift above secondary alone is shown
above. ERK phosphorylation was increased with a combination of hypoxia and
prostaglandin E2 treatment (n=4, p=0.15) when compared with untreated cells.
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Supplementary Figure 5 Cell cycle progression after hypoxia or combination hypoxia
and prostaglandin E2 treatment.

Cell cycle progression after hypoxia or combination hypoxia and prostaglandin E2
treatment. Cardiac progenitors were incubated for 48 hours with hypoxia (1% Oxygen) or
a combination of hypoxia and prostaglandin E2. For the combination treatment, cardiac
progenitors were treated with 48 hours of hypoxia (followed by 6 hours of normal culture
conditions for acclimatization) then 6 hours 10µM prostaglandin E2 in normal growth
medium. Cell cycle progression was not significantly altered by treatment with hypoxia
alone (n=4), or a combination of hypoxia and PGE2 (n=4) when compared with untreated
cells.
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Supplementary Figure 6 Migration in cardiovascular progenitors after consecutive
treatment with hypoxia and PGE2.

Cardiac progenitor cell clones were cultured in a hypoxia chamber for 48 hours, then 6
hours of normal culture conditions, followed by 6 hours of 10µM PGE2. Migration was
assessed using a transwell migration assay. Combination treatment increased migration
but not significantly (9083 vs 5455 cells, p=0.07).
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Supplementary Table 1 Cell surface phenotype of neonatal and adult CPCs as
identified by flow cytometry.
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Supplementary Table 2 Antibodies used to characterize cell surface markers
expressed on neonatal and adult CPC clones.
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Supplementary Table 3 Relative expression of significantly altered microRNAs
in neonatal and adult cardiovascular progenitors.
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Supplementary Table 4 Pathway analysis associated with microRNAs that were
differentially regulated when comparing neonatal and adult CPCs
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Supplementary Table 5 Relative expression of significantly altered microRNAs
in SSEA-4+ neonatal and adult cardiovascular progenitors
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Supplementary Table 6 Primers used to detect gene expression by PCR
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Supplementary Table 7 Primers used for Real-time PCR
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